The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
Formula granule business under VBP配方颗粒集采业务
7 · 2024-01-03 → 2025-05-06
▾
The traditional Chinese medicine formula granule business navigates declining prices and margins due to national standard transitions and provincial volume-based procurement.中药配方颗粒业务应对国家标准转换和省级集采带来的价格与毛利下行。
2024-01-03China Resources Sanjiu stated that due to volume-based procurement and national standard transition, its formula granule business proportion declined; expects price drops and revenue impact over the next 2-3 years, but profit impact is relatively small.华润三九表示，受集采和国标切换影响，配方颗粒业务占比下降；预计未来2-3年产品价格下降并对营收有影响，但对利润端影响相对较小。
2024-03-22China Resources Sanjiu's prescription drug business revenue fell 12.64% YoY to RMB 5.22 billion in 2023, mainly due to national standard transition and 15-province alliance centralized procurement impacting traditional Chinese medicine formula granules.华润三九2023年处方药业务营收52.20亿元，同比下降12.64%，主要受中药配方颗粒国标切换及15省联盟集采影响。
2024-05-15Investor relations record disclosed that formula granule products saw an average price drop of about 40% in Shandong 15-province joint procurement, impacting gross margin.投资者关系记录披露，配方颗粒产品在山东十五省联采中平均降价约40%，影响毛利率。
2024-07-30China Resources Sanjiu said its formula granule business performed steadily in Q1 2024 and is expected to have some growth space for the full year.华润三九表示配方颗粒业务2024年一季度表现稳定，预期全年有一定增长空间。
2025-02-27China Resources Sanjiu stated it will leverage the first-mover advantage of its formula granule pilot enterprise status to maintain a leading position amid policies expanding TCM formula granules and decoction pieces into medical insurance.华润三九表示将利用配方颗粒试点企业的先发优势，在多地中药配方颗粒和饮片纳入医保的政策下保持领先地位。
2025-04-16China Resources Sanjiu stated that its main prescription drug varieties have been largely included in centralized procurement (VBP), and the impact of TCM VBP has been largely absorbed.华润三九表示，公司主要的处方药品种已基本纳入集采，中成药集采的影响已有所消化。
2025-05-06China Resources Sanjiu stated that most of its prescription drugs have been included in centralized procurement (VBP), and the impact of TCM VBP has been largely absorbed.华润三九表示其主要处方药品种已基本纳入集采，中成药集采的影响已有所消化。
Runsheng Pharmaceutical stake润生药业股权
2 · 2024-01-05 → 2024-10-25
▾
Progressive equity investment in respiratory drug developer Runsheng Pharmaceutical, culminating in becoming its largest shareholder.逐步增资呼吸科药物开发商润生药业，最终成为其第一大股东。
2024-01-05China Resources Sanjiu acquired stakes in Runsheng Pharmaceutical (respiratory drug developer) from existing shareholders for RMB 58.91 million and injected RMB 102.38 million, obtaining 4.19% equity post-transaction.华润三九以5891万元受让润生药业现有股东部分股权，并增资1.0238亿元，完成后获得润生药业4.19%股权。
2024-10-25Increased stake in Runsheng Pharmaceutical to 23.57%, becoming its largest shareholder, through share transfer and capital increase.通过受让股权及增资方式增持润生药业至23.57%，成为其第一大股东。
Strategic cooperation MoUs战略合作备忘录
8 · 2024-01-05 → 2025-12-12
▾
Cooperation meetings and agreements with distributors, local governments, and industry partners to expand market reach and build supply chains.与经销商、地方政府及行业伙伴的合作会议与协议，旨在拓展市场覆盖和构建供应链。
2024-01-05China Resources Sanjiu and Leyao Group held a strategic cooperation meeting, reaching initial consensus on 2024 cooperation to leverage digital marketing for expanding into broad and sinking markets.华润三九与乐药集团举行战略合作沟通会，初步达成2024年合作共识，借助数字化营销网络拓展广阔下沉市场。
2024-04-15China Resources Sanjiu Chairman Qiu Huawei met with Bozhou city officials to discuss traditional Chinese medicine enterprise M&A and TCM variety R&D, reaching multiple cooperation intentions.华润三九董事长邱华伟与亳州市委书记杜延安会面，就中药企业并购、中药品种研发等进行交流，达成多项合作意向。
2024-10-15China Resources Sanjiu held a strategic meeting with China National Medicines Corporation (Guoda Pharmacy), China Resources Jiangzhong, Dong'e Ejiao, Kunming Pharma, and China Resources Zizhu; launched a brand co-building base.华润三九与国大药房、华润江中、东阿阿胶、昆药集团、华润紫竹举行战略沟通会，并启动品牌共建基地。
2025-07-11Held mid-year review meeting with Yaoyigou (药易购) to deepen cooperation in brand marketing, channel construction, and market promotion.与药易购召开年中总结会议，深化在品牌营销、渠道建设和市场推广等方面的合作。
2025-08-29China Resources Sanjiu and Jointown (九州通) launched the 'Tianyuan Plan' industry-commerce-retail co-building project to optimize supply chain collaboration.华润三九与九州通携手打造“天元计划·工商零共建项目”，旨在优化供应链协同。
2025-10-16Quanzhou municipal party secretary and mayor met with China Resources Sanjiu chairman Qiu Huawei; the company expressed willingness to expand cooperation and implement more health industry R&D and production projects in Quanzhou.泉州市委书记、市长会见华润三九董事长邱华伟；华润三九表示将加强与泉州交流对接，谋划实施更多大健康产业研发生产项目。
2025-12-06China Resources Sanjiu signed a strategic cooperation agreement with Dongfanghong Xiyangshen Pharmaceutical (Tonghua) focusing on ginseng-based Chinese medicine slices and deep processing, building a full-chain R&D-production-sales ecosystem.华润三九与东方红西洋参药业（通化）签署战略合作协议，聚焦参类中药饮片及深加工领域，构建研发-生产-销售全链条协同生态。
2025-12-12China Resources Sanjiu joined JD Health's 'Influenza Drug Supply and Price Stability Alliance' with 25 other pharmaceutical companies to ensure supply and stable prices during the flu season.华润三九联合京东买药秒送及25家药企成立“流感药品保供稳价联盟”，保障流感季药品供应和价格稳定。
Executive leadership transitions高管层变动
21 · 2024-01-12 → 2026-07-14
▾
A series of changes in the board, presidency, CFO, and other key executive roles, including the appointment of Wu Wenduo as President.董事会、总裁、CFO及其他关键高管的一系列变动，包括吴文多被任命为总裁。
2024-01-12Independent director Liu Junyong resigned from China Resources Sanjiu board due to work needs; he will continue duties until a replacement is elected.独立董事刘俊勇因工作需要辞去华润三九董事会独立董事及审计委员会主任委员职务，在新任独立董事到任前继续履职。
2024-03-13China Resources Sanjiu's director and president Zhao Bingxiang resigned due to job change, ceasing all positions in the company.华润三九董事、总裁赵炳祥因工作变动辞职，不再担任公司任何职务。
2024-04-02Zhao Bingxiang, former President of China Resources Sanjiu, was appointed as Deputy Secretary of the Party Committee and Director of Sinopharm Group (国药集团), and nominated as General Manager.华润三九原总裁赵炳祥被任命为国药集团党委副书记、董事，并提名为总经理人选。
2024-05-16Board of directors elected a new chairman (details not specified in items).董事会选举了新董事长（具体人选未在条目中说明）。
2024-05-16Elected Zhang Jihong and Zhao Lan as employee representative supervisors for the 9th Supervisory Board, term of 3 years.选举张继红、赵兰为第九届监事会职工代表监事，任期三年。
2024-05-24Vice President Guo Ting resigned due to job changes, effective immediately; continues as director in subsidiaries.副总裁郭霆因工作变动辞职，即日生效，继续在子公司担任董事。
2024-07-31China Resources Sanjiu appointed Liang Zheng as the new Board Secretary, effective from the 14th Board meeting on July 31, 2024, for the term concurrent with the 9th Board of Directors.华润三九聘任梁征担任公司董事会秘书，任期与公司第九届董事会任期一致，自2024年7月31日董事会会议审议通过。
2024-08-09CR Sanjiu announced the resignation of supervisor Tang Na due to work changes, effective upon delivery of the resignation report to the board of supervisors.华润三九公告监事唐娜因工作变动辞职，辞职报告送达监事会时生效。
2024-08-23CR Sanjiu's board of supervisors nominated Zhou Jiao as a candidate for supervisor to replace Tang Na, with term concurrent with the 9th board of supervisors.华润三九监事会提名周娇为监事候选人以接替唐娜，任期与第九届监事会一致。
2024-09-06Director Liang Zheng resigned from the board but remains CFO and Board Secretary; Vice President Xu Yongqian resigned and left the company.董事梁征辞去董事职务，但继续担任财务总监和董事会秘书；副总裁徐永前辞职并离开公司。
2024-09-06The board appointed Wu Wenduo as President and nominated him as a director candidate; he was previously Vice President of China Resources Double-Crane.董事会聘任吴文多为总裁，并提名其为董事候选人；其此前担任华润双鹤副总裁。
2024-10-14Zhao Bingxiang resigned as legal representative and general manager; Wu Wenduo succeeded as legal representative and manager.赵炳祥卸任法定代表人、总经理，由吴文多接任法定代表人并担任经理。
2024-10-24Director Yang Xudong resigned from the board and the Remuneration and Appraisal Committee due to work changes.董事杨旭东因工作变动辞去公司董事及薪酬与考核委员会委员职务。
2024-10-24Vice President Wang Yanfei resigned due to work arrangements, but will remain in other positions within the company.副总裁王雁飞因工作安排辞去副总裁职务，但继续在公司担任其他职务。
2024-11-29China Resources Sanjiu's CFO and Board Secretary Liang Zheng resigned due to job changes; President Wu Wenduo will act as CFO, and VP Zhou Hui as Board Secretary, for up to three months.华润三九财务总监、董事会秘书梁征因工作变动辞职；总裁吴文多代行财务总监职责，副总裁周辉代行董事会秘书职责，期限不超过三个月。
2024-12-02CFO and Board Secretary Liang Zheng resigned due to job change, effective immediately; President Wu Wendo will act as CFO, VP Zhou Hui as acting Board Secretary for up to 3 months.财务总监兼董事会秘书梁征因工作变动辞职，即日生效；总裁吴文多代行财务总监职责，副总裁周辉代行董事会秘书职责不超过三个月。
2025-02-28China Resources Sanjiu's third board meeting in 2025 approved the appointment of a new CFO and board secretary.华润三九2025年第三次董事会会议审议通过了聘任财务总监、董事会秘书的议案。
2025-06-24Vice President Huang Xianfeng resigned due to work adjustment, will continue as full-time deputy secretary of the Party Committee; he held no shares.副总裁黄先锋因工作调整辞职，将继续担任党委专职副书记；未持有公司股票。
2025-12-26Director Cui Xingpin resigned due to work adjustment; Huang Xianfeng was elected as employee representative director at the 9th Board of Directors.董事崔兴品因工作调整辞职；黄先锋当选第九届董事会职工董事。
2026-01-05Board meeting approved change of internal audit head; Zhong Jiang resigned as GM of audit department.董事会会议批准内部审计负责人变更；钟江不再担任审计部总经理。
2026-07-14Executive Zhou Hui resigned as director, VP, general counsel, and chief compliance officer due to retirement; remains director at subsidiary.周辉因退休辞去董事、副总裁、总法律顾问、首席合规官职务，继续在子公司担任董事。
Research institutes & subsidiaries研究院与子公司
2 · 2024-01-12 → 2024-05-30
▾
Establishment and certification of research centers, subsidiaries, and related infrastructure for TCM innovation and packaging.设立和认证中药创新及包装相关的研究中心、子公司及配套设施。
2024-01-12China Resources Sanjiu Traditional Chinese Medicine Inheritance and Innovation Center (Hezhou Base) intelligent pharmacy (decoction center) was officially inaugurated in Hezhou City.华润三九中医药传承创新中心（贺州基地）智能中药房（代煎中心）在贺州市正式揭牌启用。
2024-05-30Subsidiary Shenzhen Jiuxing Printing & Packaging Group was re-certified as 'China Pharmaceutical Packaging R&D Center' by China Packaging Federation.子公司深圳九星印刷包装集团再次获中国包装联合会授牌‘中国医药包装研发中心’。
Product development & licensing产品开发与授权
4 · 2024-01-16 → 2026-06-24
▾
In-licensing, co-development, and R&D procurement for new drugs and health products.新药和健康产品的引进许可、联合开发及研发采购。
2024-01-16China Resources Sanjiu's subsidiary Sichuan Sanjiu signed a product sales cooperation agreement with CR Tianjin Bio and CR Angde Bio to be exclusive promoter for Reteplase, Interleukin-11, and Epoetin alfa in mainland China, with total transaction value up to RMB 200 million (2024: ≤85M, 2025: ≤115M).华润三九子公司四川三九与华润天津生物、华润昂德生物签署产品销售合作协议，成为瑞通立、百杰依、佳林豪在大陆的独家推广服务商，总交易金额不超过2亿元。
2025-11-10China Resources Sanjiu obtained exclusive rights from Langyu Group and Bioproject to develop, produce and commercialize the innovative drug 'Huakesi' (pitolisant tablets) for narcolepsy in mainland China; the drug is the first non-psychotropic controlled narcolepsy treatment in China, already included in national medical insurance.华润三九与琅钰集团、Bioproject三方签约，获得创新药‘铧可思（替洛利生片）’在中国大陆开发、生产和商业化的独占权利；该药是国内首个获批用于发作性睡病的非精神管控类药物，已纳入国家医保。
2026-05-27China Resources Sanjiu initiated a technical due diligence service procurement for a metabolic drug commercialization rights project in Hubei Province.华润三九启动湖北省某代谢领域药品商业化权益项目技术尽调服务采购。
2026-06-24Launched procurement for domestic compound health food innovative design project (国产复方配伍保健食品创新设计项目); bid deadline July 10, 2026.发布国产复方配伍保健食品创新设计项目采购公告，响应截止日期2026年7月10日。
Online B2C & digital marketing growth线上B2C与数字营销增长
2 · 2024-01-22 → 2024-07-30
▾
Strategic push to grow online B2C sales share and implement digital marketing, exceeding the 10% revenue share target.战略性地提升线上B2C销售占比并实施数字营销，已超过10%的收入占比目标。
2024-01-22China Resources Sanjiu stated that its online B2C business currently accounts for about 5% of CHC business; it aims to increase this to over 10% during the 14th Five-Year Plan period.华润三九表示，目前线上B2C业务占CHC业务比重约5%，十四五期间希望提升至10%以上。
2024-07-30China Resources Sanjiu disclosed that its online business revenue share exceeded 10% under its digital marketing strategy, and it targets to control the sales expense ratio below 30% in the future.华润三九披露线上业务占比已超过10%，未来销售费用率管控目标为控制在30%以下。
Annual & quarterly financial results年度与季度财务业绩
31 · 2024-01-24 → 2026-07-14
▾
Reporting of periodic financial results, including revenue and profit guidance, and analysis of segment performance.定期财务业绩报告，包括收入和利润指引，以及分部业绩分析。
2024-01-24China Resources Sanjiu released 2023 performance forecast: net profit attributable to shareholders RMB 2.818-3.065 billion, up 15.08%-25.16% YoY; growth driven by Kunming Pharma consolidation and CHC business.华润三九发布2023年业绩预告：归母净利润28.18-30.65亿元，同比增长15.08%-25.16%，增长由昆药集团并表和CHC业务带动。
2024-03-22China Resources Sanjiu reported 2023 annual results: revenue RMB 24.739 billion, up 36.83% YoY; net profit attributable to shareholders RMB 2.853 billion, up 16.5% YoY; EPS RMB 2.90. Proposed cash dividend of RMB 15 per 10 shares and capital reserve increase of 3 shares per 10 shares.华润三九发布2023年年报：营业收入247.39亿元，同比增长36.83%；归母净利润28.53亿元，同比增长16.5%；基本每股收益2.90元。拟每10股派发现金红利15元并转增3股。
2024-03-22China Resources Sanjiu guided 2024 revenue to achieve double-digit growth, with net profit matching revenue growth level.华润三九预计2024年营业收入实现双位数增长，净利润匹配营收增长水平。
2024-04-02At the 2023 annual results briefing, China Resources Sanjiu Chairman Qiu Huawei guided 2024 revenue to achieve double-digit growth, with net profit matching revenue growth.在2023年度业绩说明会上，华润三九董事长邱华伟预计2024年营业收入将实现双位数增长，净利润匹配营收增长水平。
2024-04-02China Resources Sanjiu reported 2023 annual results: revenue of RMB 24.739 billion, up 36.83% YoY; net profit of RMB 2.853 billion, up 16.50% YoY.华润三九发布2023年年报：营业收入247.39亿元，同比增长36.83%；净利润28.53亿元，同比增长16.50%。
2024-04-19China Resources Sanjiu released Q1 2024 results: revenue of RMB 7.294 billion, up 14.82% YoY; net profit attributable to shareholders of RMB 1.364 billion, up 18.49% YoY; basic EPS of RMB 1.39.华润三九发布2024年一季报：营业收入72.94亿元，同比增长14.82%；归母净利润13.64亿元，同比增长18.49%；基本每股收益1.39元。
2024-04-23China Resources Sanjiu stated at the Q1 2024 results briefing that the comprehensive gross margin was 53.42%, down 0.65% YoY, but excluding the consolidation of KPC Pharmaceuticals, the gross margin was stable with a slight uptick.华润三九在2024年一季度业绩说明会上表示，综合毛利率为53.42%，同比下降0.65%，剔除昆药并表影响后毛利率稳中有升。
2024-08-23CR Sanjiu reported H1 2024 results: revenue RMB 14.106 billion (+7.30% YoY), net profit attributable to shareholders RMB 2.398 billion (+27.77% YoY), EPS RMB 1.87.华润三九发布2024年半年度报告：营业收入141.06亿元（同比+7.30%），归母净利润23.98亿元（同比+27.77%），基本每股收益1.87元。
2024-08-23CR Sanjiu's H1 2024 operating cash flow was RMB 2.363 billion (+33.36% YoY); net cash flow was -RMB 1.06 billion, down 129.17% YoY, mainly due to investment and financing activities.华润三九2024年上半年经营性现金流23.63亿元（同比+33.36%）；净现金流-10.6亿元，同比下滑129.17%，主要受投资和融资活动影响。
2024-10-25Q3 2024 results: revenue RMB 19.74 billion (+6.08% YoY), net profit attributable to shareholders RMB 2.96 billion (+23.19% YoY).2024年三季报：营业收入197.4亿元（同比+6.08%），归母净利润29.60亿元（同比+23.19%）。
2024-11-04China Resources Sanjiu reported Q3 2024 results: 9M revenue RMB 19.74 billion (+6.08% YoY), net profit RMB 2.96 billion (+23.19% YoY); Q3 revenue RMB 5.634 billion (+3.16% YoY), net profit RMB 556 million (+6.85% YoY), but Q3 non-GAAP net profit fell 6.83% YoY to RMB 444 million.华润三九发布2024年三季报：前三季度营收197.4亿元（同比+6.08%），归母净利润29.6亿元（同比+23.19%）；单三季度营收56.34亿元（同比+3.16%），归母净利润5.56亿元（同比+6.85%），但三季度扣非净利润同比下降6.83%至4.44亿元。
2025-02-10China Resources Sanjiu released 2024 annual performance: revenue of RMB 27.617 billion (+11.63% YoY), net profit attributable to shareholders of RMB 3.369 billion (+18.10% YoY), basic EPS of RMB 2.63.华润三九发布2024年度业绩快报：营业总收入276.17亿元（同比+11.63%），归母净利润33.69亿元（同比+18.10%），基本每股收益2.63元。
2025-03-12China Resources Sanjiu reported 2024 annual results: revenue of 27.617 billion yuan (+11.63% YoY), net profit of 3.368 billion yuan (+18.05% YoY), and proposed a dividend of 3.2 yuan per 10 shares plus a 3-for-10 capital reserve increase.华润三九发布2024年年报：营业收入276.17亿元（同比+11.63%），净利润33.68亿元（同比+18.05%），拟每10股派现3.2元并转增3股。
2025-04-01China Resources Sanjiu reported 2024 annual results: revenue of 27.617 billion yuan, net profit of 3.368 billion yuan; CHC health consumer business revenue of 12.482 billion yuan (+14.13% YoY), prescription drug business revenue of 6.006 billion yuan (+15.04% YoY), and traditional Chinese medicine (Kunming Pharma) business revenue of 5.213 billion yuan.华润三九公布2024年业绩：营业收入276.17亿元，净利润33.68亿元；CHC健康消费品业务营收124.82亿元（同比增长14.13%），处方药业务营收60.06亿元（同比增长15.04%），传统国药（昆药）业务营收52.13亿元。
2025-04-28China Resources Sanjiu reported Q1 2025 results: revenue of 6.854 billion yuan (-6.04% YoY), net profit of 1.27 billion yuan (-6.87% YoY); operating cash flow of 980 million yuan (+24.57% YoY); R&D expenses of 145 million yuan (+5.15% YoY).华润三九发布2025年第一季度报告：营业收入68.54亿元（同比下降6.04%），净利润12.70亿元（同比下降6.87%）；经营活动现金流净额9.80亿元（同比增长24.57%）；研发费用1.45亿元（同比增长5.15%）。
2025-05-06China Resources Sanjiu reported Q1 2025 revenue of 68.54 billion yuan (-6.04% YoY) and net profit of 12.70 billion yuan (-6.87% YoY), due to high base from lower flu/respiratory disease incidence and weak pharmacy retail.华润三九公布2025年一季度营收68.54亿元（同比-6.04%），归母净利润12.70亿元（同比-6.87%），因流感/呼吸道疾病发病率降低及实体药店零售疲软的高基数影响。
2025-06-06Q1 2025 revenue fell 6.04% YoY to 68.54 billion yuan, net profit attributable to parent fell 6.87% to 12.7 billion yuan.2025年一季度营收同比下降6.04%至68.54亿元，归母净利润同比下降6.87%至12.7亿元。
2025-08-15China Resources Sanjiu released 2025 H1 results: revenue CNY 14.81 billion (+4.99% YoY), net profit CNY 1.815 billion (-24.31% YoY). Proposed interim dividend of CNY 4.5 per 10 shares (total ~CNY 751 million).华润三九发布2025年半年度业绩：营业收入148.10亿元（同比+4.99%），归母净利润18.15亿元（同比-24.31%）。拟每10股派发现金红利4.5元（合计约7.51亿元）。
2025-08-15China Resources Sanjiu's 2025 H1 CHC (self-care) revenue fell 17.89% YoY to CNY 7.994 billion; prescription drug revenue surged 100.18% YoY to CNY 4.838 billion, partly due to Tasly consolidation.华润三九2025年上半年CHC（自我诊疗）业务收入同比下降17.89%至79.94亿元；处方药业务收入同比增长100.18%至48.38亿元，部分受天士力并表影响。
2025-08-17China Resources Sanjiu held a 2025 H1 results investor call on August 17, stating that revenue growth included Tasly consolidation; excluding Tasly, revenue slightly declined. Net profit drop was mainly due to a high base in 2024 H1.华润三九于8月17日举行2025年半年报业绩电话沟通会，表示营收增长包含天士力并表，剔除后营收略有下降；净利润下降主要由于2024年上半年高基数。
2025-09-02China Resources Sanjiu reported H1 2025 revenue of RMB 14.810 billion, up 4.99% YoY; net profit attributable to parent fell 24.31% YoY to RMB 1.815 billion. Its core self-diagnosis (CHC) and traditional Chinese medicine (Kunming Pharma) businesses saw revenue declines of 18.39% and 16.18% YoY respectively, with gross margins down 2.43 ppt and 5.36 ppt.华润三九2025年上半年营收148.10亿元，同比增长4.99%；归母净利润18.15亿元，同比下降24.31%。核心自我诊疗（CHC）及传统国药（昆药）业务营收同比分别下滑18.39%和16.18%，毛利率分别减少2.43和5.36个百分点。
2025-10-24China Resources Sanjiu released Q3 2025 report: 9M revenue 21.986 billion yuan (+11.38% YoY), net profit attributable to shareholders 2.353 billion yuan (-20.51% YoY); Q3 revenue 7.176 billion yuan (+27.37% YoY), net profit 538 million yuan (-4.26% YoY).华润三九发布2025年三季报：前三季度营业收入219.86亿元（同比+11.38%），归母净利润23.53亿元（同比-20.51%）；第三季度营业收入71.76亿元（同比+27.37%），归母净利润5.38亿元（同比-4.26%）。
2025-10-24China Resources Sanjiu's board of directors approved the Q3 2025 report and other resolutions at its 12th meeting of 2025.华润三九董事会2025年第十二次会议审议通过了2025年第三季度报告等议案。
2025-11-01China Resources Sanjiu reported 2025 Q3 revenue of 21.99 billion yuan, up 11.4% YoY; net profit attributable to parent fell 20.5% to 2.35 billion yuan; operating cash flow was 2.925 billion yuan, down 8.7%.华润三九公布2025年三季报，营业收入219.9亿元，同比上升11.4%；归母净利润23.5亿元，同比下降20.5%；经营现金流净额29.25亿元，同比下降8.7%。
2025-11-14China Resources Sanjiu stated in investor relations that it expects 2025 revenue to exceed industry average growth, aiming for double-digit growth, while maintaining stable profits.华润三九在投资者关系活动中表示，预计2025年营业收入将超越行业平均增速，努力实现双位数增长，利润端保持稳健。
2026-03-20China Resources Sanjiu announced 2025 annual results: revenue of 31.603 billion yuan (+14.43% YoY), net profit of 3.421 billion yuan (+1.58% YoY), proposed cash dividend of 5.9 yuan per 10 shares (tax incl.).华润三九公布2025年年报：营业收入316.03亿元（同比+14.43%），净利润34.21亿元（同比+1.58%），拟每10股派发现金红利5.9元（含税）。
2026-03-202025 annual report shows operating cash flow of 5.513 billion yuan, up 25.23% YoY.2025年年报显示经营活动现金流净额55.13亿元，同比增长25.23%。
2026-04-08CHC respiratory category remained stable despite lower flu incidence and high base; skin, stomach, vitamins/minerals categories grew; expects 2026 revenue to beat industry average.CHC业务呼吸品类在流感发病率降低和高基数下保持稳健；皮肤、胃药、维矿等品类保持增长；预计2026年营业收入将超越行业平均增速。
2026-04-242026 Q1 revenue 8.13 bln yuan, +18.62% YoY; net profit 1.076 bln yuan, -15.29% YoY; EPS 0.65 yuan.2026年第一季度营业收入81.3亿元，同比增长18.62%；净利润10.76亿元，同比下降15.29%；基本每股收益0.65元。
2026-06-232025 annual results: revenue RMB 31.603 billion (+14.43% YoY), net profit RMB 3.421 billion (+1.58% YoY). 2026 Q1 results: revenue RMB 8.13 billion (+18.62% YoY), net profit RMB 1.076 billion (-15.29% YoY).2025年年报：营收316.03亿元（同比+14.43%），净利润34.21亿元（同比+1.58%）；2026年一季报：营收81.3亿元（同比+18.62%），净利润10.76亿元（同比-15.29%）。
2026-07-14H1 2026 results: revenue 15.013B yuan (+1.37% YoY), net profit 1.672B yuan (-7.90% YoY), non-GAAP net profit 1.598B yuan (-5.87%).2026年上半年业绩快报：营业收入150.13亿元，同比增长1.37%；归母净利润16.72亿元，同比下降7.90%；扣非净利润15.98亿元，同比下降5.87%。
999 Ganmaoling cold medicine capacity999感冒灵产能
13 · 2024-01-26 → 2026-07-28
▾
Persistent supply shortages of the core cold medicine 999 Ganmaoling due to capacity bottlenecks, addressed through the Chenzhou South China manufacturing center and ongoing expansion projects.核心感冒药999感冒灵因产能瓶颈持续供不应求，通过郴州华南制造中心及扩产项目解决。
2024-01-26China Resources Sanjiu disclosed in investor relations activity that it faces capacity bottlenecks for Ganmaoling (cold medicine) and is carrying out capacity expansion projects, expected to improve in 2024.华润三九在投资者关系活动中披露，感冒灵订单充裕但存在产能瓶颈，正在开展产能扩充项目，预计2024年改善。
2024-02-07Company disclosed that 999 Ganmaoling (cold medicine) orders are ample but capacity is constrained; capacity expansion projects are underway and expected to improve in 2024.公司披露999感冒灵订单充裕但产能有瓶颈，产能扩充项目预计2024年改善。
2024-05-11Core product 999 Fufang Ganmaoling Granules experienced supply shortages due to insufficient capacity; company denied bundling sales.核心产品999复方感冒灵颗粒因产能不足出现缺货，公司否认捆绑销售。
2024-05-15Investor relations record indicated that the new production base in Chenzhou, Hunan (southern China manufacturing center) started production in late 2023, easing cold medicine capacity pressure in 2024.投资者关系记录显示，湖南郴州华南区生产制造中心于2023年底投产，预计2024年缓解感冒药产能压力。
2024-06-06China Resources Sanjiu stated in an investor survey that its CHC business performed well in Q1, with cold medicines continuing to sell well; the Huarun Sanjiu (Chenzhou) South China manufacturing center started production in late 2023, and capacity is ramping up, expected to ease cold medicine capacity tightness by H2 2024.华润三九在投资者调研中表示，一季度CHC业务表现良好，感冒药持续旺销；华润三九（郴州）华南区生产制造中心已于2023年底投产，产能爬坡中，预计2024年下半年感冒药产能紧张状况缓解。
2024-07-30China Resources Sanjiu stated that its cold medicine category has been in strong supply and demand for the past year, with capacity pressure. The Chenzhou South China manufacturing center started production at end-2023, and capacity is expected to gradually ease in H2 2024.华润三九表示感冒品类过去一年持续供销两旺，产能面临压力；郴州华南区生产制造中心已于2023年底投产，预计2024年下半年感冒药产能紧张状况会有所缓解。
2025-01-14China Resources Sanjiu disclosed in an investor relations activity that it achieved recovery growth in 2024 above industry average, with cold, stomach, skin, and hepatobiliary categories performing well; inventory of cold products is normal at about 2.5 months; two rounds of capacity expansion are underway.华润三九在投资者关系活动中披露，2024年实现恢复性增长并超越行业平均增速，感冒、胃药、皮肤和肝胆品类表现良好，感冒品类库存约2.5个月，正在进行两轮产能扩张。
2025-04-23China Resources Sanjiu's Ganmaoling Granules achieved sales of 2.59 billion yuan in China's urban physical pharmacy terminal in 2024, with a growth rate of 10.39%, making it one of two TCM brands exceeding 2 billion yuan.华润三九的感冒灵颗粒2024年在中国城市实体药店终端销售额达25.9亿元，增长率为10.39%，成为销售额超20亿元的两个中成药品牌之一。
2025-05-15China Resources Sanjiu (Chenzhou) South China manufacturing center achieved 100% CNC rate of key equipment and 90% equipment networking rate, doubling production capacity through 11 smart manufacturing scenarios.华润三九（郴州）华南区生产制造中心实现关键设备数控化率100%、联网率90%，通过11个智能制造场景使产能翻倍。
2026-01-21Awarded 2026 999 Ganmaoling social marketing project to Beijing Tima Creative Culture Co., Ltd.2026年999感冒灵社会化营销项目成交供应商为北京缇玛创意文化有限公司。
2026-01-28Awarded entrusted production of Ganmaoling Granules (2026, Zaozhuang) to China Resources Sanjiu (Zaozhuang) Pharmaceutical Co., Ltd.感冒灵颗粒2026年枣庄地区委托生产服务商为华润三九（枣庄）药业有限公司。
2026-07-03Announced procurement for strategic extension product development strategy services for 999 Ganmaoling and Sanjiu Weitai Yangweishu.发布999感冒灵-三九胃泰养胃舒战略延伸产品开发策略服务项目采购公告。
2026-07-28NMPA issued announcement No. 66 to uniformly revise instructions for all oral Ganmaoling preparations, impacting 999 Ganmaoling.国家药监局发布第66号公告，对感冒灵口服制剂说明书实施统一修订，影响999感冒灵。
R&D pipeline & innovation system研发管线与创新体系
16 · 2024-02-05 → 2026-08-20
▾
Buildout of the 'Six Institutes, Three Labs' R&D system, increased R&D spending, and progress across a broad pipeline including TCM 1.1 new drugs and chemical generics.建设'六院三室'研发体系，增加研发投入，并在中药1.1类新药和化药仿制药等广泛管线取得进展。
2024-02-05China Resources Sanjiu and Zhejiang University Yangtze River Delta Smart Green Innovation Center signed an agreement to jointly build the 'Innovative Delivery Technology Joint Research Institute', focusing on nano-delivery technology platforms.华润三九与浙江大学长三角智慧绿洲创新中心签约共建'创新递送技术联合研究院'，聚焦纳米递送技术平台。
2024-04-17China Resources Sanjiu's Dahealth (Shenghai) Business Unit and the Nanjing Wild Plant Comprehensive Utilization Research Institute of the All China Federation of Supply and Marketing Cooperatives signed a strategic agreement to establish the 'Medicine-Food Homology Industry Joint Laboratory'.华润三九大健康（圣海）事业部与中华全国供销合作总社南京野生植物综合利用研究院签约，成立“药食同源产业联合实验室”。
2024-06-18China Resources Sanjiu disclosed that its Loxoprofen Sodium Gel Patch is currently in the registration and application stage.华润三九披露洛索洛芬钠凝胶贴膏目前在注册申报中。
2025-03-12China Resources Sanjiu reported 2024 R&D spending of 953 million yuan, with 131 projects in pipeline focusing on oncology, orthopedics, dermatology, respiratory, and anti-infection areas.华润三九2024年研发投入9.53亿元，在研项目131项，聚焦抗肿瘤、骨科、皮肤、呼吸、抗感染等领域。
2025-04-03China Resources Sanjiu disclosed that R&D investment increased from 581 million yuan (2020) to 953 million yuan (2024), a growth of about 64% during the 14th Five-Year Plan period.华润三九披露研发投入从2020年的5.81亿元提升至2024年的9.53亿元，“十四五”期间增幅达64%左右。
2025-07-31Newly registered software copyright for 'Calcium Carbonate D3 Mixed Production Process Online Uniformity Real-time Monitoring System V1.0'; R&D spending in 2024 was 802 million yuan, up 12.21% YoY.新注册《碳酸钙D3混合生产过程在线均一性实时监测系统V1.0》软件著作权；2024年研发投入8.02亿元，同比增长12.21%。
2025-10-13China Resources Sanjiu stated in an investor Q&A that it has established a 'Six Institutes, Three Labs' R&D system, focusing on innovation-driven strategy in self-care (CHC) and prescription drug fields, building a diversified product matrix and R&D pipeline.华润三九在投资者问答中表示，已设立“六院三室”研发体系，坚持创新驱动战略，在自我诊疗和处方药领域构建多元化产品矩阵和研发管线梯队。
2025-11-19China Resources Sanjiu's TCM Category 1.1 new drug Xiao'er Anshen Bugu Granules received clinical trial implied approval from CDE, intended for pediatric tic disorder with spleen deficiency and phlegm accumulation syndrome.华润三九的中药1.1类新药小儿安神补脑颗粒获得CDE临床试验默示许可，拟用于儿童抽动障碍脾虚痰聚、风痰上扰证。
2025-11-19China Resources Sanjiu disclosed that it has 9 TCM Category 1.1 new drugs in Phase III clinical trials or beyond, including Anshen Dripping Pills (insomnia) under review for marketing, and 7 others in Phase III.华润三九披露已有9款中药1.1类新药处于III期临床及以上阶段，其中安神滴丸（失眠症）已报产在审，另有7款处于III期临床。
2026-03-202025 annual report shows R&D investment of 1.734 billion yuan, with 203 projects in pipeline focusing on cardiovascular, cerebrovascular, oncology, digestive metabolism, and cold/respiratory areas.2025年年报显示研发投入17.34亿元，在研项目共203项，聚焦心脑血管、肿瘤、消化代谢、感冒呼吸等领域。
2026-04-202025 R&D spending 1.734 bln yuan; 203 projects in pipeline focusing on cardiovascular, oncology, digestion/metabolism, and respiratory areas.2025年研发投入17.34亿元，在研项目共计203项，主要围绕心脑血管、肿瘤、消化代谢、感冒呼吸等治疗领域。
2026-04-21Launched a tender for a brain health digital innovation product research project, including gamified C-end products and doctor prescription/in-hospital application feasibility.发布脑健康数字化创新产品研究项目招标，包括游戏化C端产品和医生处方/院内应用可行性分析。
2026-06-24Completed procurement for brain health digital innovation product research project; supplier is Chongqing Artery Orange Technology Co., Ltd.脑健康数字化创新产品研究项目采购完成，成交供应商为重庆动脉橙科技有限公司。
2026-07-08Won 2025 National Science and Technology Progress Award (Second Class) for project on TCM mechanism analysis technology system.参与的《以功效物质为核心的中药作用原理解析创新技术体系构建与应用》项目荣获2025年度国家科学技术进步奖二等奖。
2026-08-19Nature Medicine published 12-month follow-up of HEAL-CHF trial: iPSC-derived cardiomyocyte drug HiCM-188 (co-developed with Epergen Regenerative Medicine) showed 90% of cell-treated severe ischemic heart failure patients improved to NYHA class II vs 60% control; 6-min walk distance +168.8m; stroke volume +9.03mL. Confirmatory trial launched in China.《自然·医学》发表HEAL-CHF试验12个月随访结果：华润三九与艾尔普再生医学联合开发的iPSC来源心肌细胞药物HiCM-188治疗重度缺血性心衰，90%细胞治疗组患者NYHA分级降至II级（对照组60%），6分钟步行距离平均提升168.8米，每搏输出量平均增加9.03mL；国内确证性临床试验已启动。
2026-08-20Procurement result: Shanghai Yaotuo Pharmaceutical Technology selected as supplier for oncology field research service project.采购结果公告：上海药拓医药科技有限公司成为肿瘤领域调研服务采购项目成交供应商。
Kunming Pharma (KPC) integration & Sanqi chain昆药整合与三七产业链
26 · 2024-02-07 → 2026-06-29
▾
Integration of Kunming Pharma, including the '777' and 'KPC 1381' brand launches, the transfer of Kunming Shenghuo to resolve Xuesaitong competition, and the buildout of the Sanqi (notoginseng) industry chain.昆药整合，包括'777'和'昆中药1381'品牌发布、转让昆明圣火解决血塞通竞争，以及三七产业链建设。
2024-02-07Company stated that the integration of Kunyao Group is progressing steadily under the first-year plan, with a new strategic goal to become 'the first health stock in the silver economy, a leader in chronic disease management, and a leader in premium traditional Chinese medicine'.公司表示昆药集团整合按首年计划稳步推进，新战略目标为'成为银发经济健康第一股、慢病管理领导者、精品国药领先者'。
2024-03-05China Resources Sanjiu's subsidiary Kunming Huarun Shenghuo signed a non-binding strategic cooperation agreement with Zhiyun Health, appointing Zhiyun as the general agent for Lixuwang Xuesaitong soft capsules in hospital channels in core sales provinces for three years.华润三九子公司昆明华润圣火与智云健康订立不具法律约束力的战略合作协议，智云健康成为理洫王牌血塞通软胶囊核心销售省份医院渠道总代理，期限三年。
2024-03-07China Resources Sanjiu and its subsidiary Kunming Pharmaceutical Group held a kick-off meeting for quality management integration project, covering nine directions including establishment of group-level quality management organization and implementation of standardized quality management system.华润三九与控股子公司昆药集团召开质量管理融合项目启动会，涵盖建立集团化质量管理机构等九个方向。
2024-03-09Kunming Pharmaceutical Group, a subsidiary of China Resources Sanjiu, launched the '777' brand at the Qingdao Sanjiu Business Conference, focusing on silver-haired health industry starting with Xuesaitong oral products.华润三九控股子公司昆药集团在青岛三九商道客户会上正式发布“777”品牌，以血塞通口服产品起步，聚焦银发健康产业。
2024-03-13China Resources Sanjiu was selected as a 'Manufacturing Single Champion Enterprise' by the Ministry of Industry and Information Technology, with champion products being Kunming Pharmaceutical Group's Luotai and Huarun Shenghuo's Lixuwang Xuesaitong soft capsules, the first such honor in China Resources Group.华润三九入选工信部“制造业单项冠军企业”，冠军产品为昆药集团“络泰”和华润圣火“理洫王”血塞通软胶囊，成为华润集团首家。
2024-04-02China Resources Sanjiu stated that the horizontal competition issue between KPC Pharmaceuticals (昆药) and Shenghuo (圣火) will be resolved within 5 years, and KPC's commercial distribution business will be divested over time.华润三九表示，昆药和圣火的同业竞争问题将在5年内解决，昆药商业流通业务将逐步剥离。
2024-04-16China Resources Sanjiu stated in an investor relations activity that KPC Pharmaceuticals' net profit margin is expected to gradually improve as its business becomes more focused and fine management improves.华润三九在投资者关系活动中表示，随着昆药集团业务聚焦和精细化管理提升，预计昆药未来净利率水平可逐渐提升。
2024-06-07China Resources Sanjiu agreed to sell 51% equity of Kunming Huarun Shenghuo Pharmaceutical to its subsidiary Kunming Pharmaceutical Group for RMB 1.791 billion, to resolve horizontal competition on Xuesaitong soft capsules and integrate the Sanqi industry chain.华润三九同意以17.91亿元向子公司昆药集团出售昆明华润圣火药业51%股权，以解决血塞通软胶囊同业竞争并整合三七产业链。
2024-06-20Kunming Pharmaceutical Group's extraordinary general meeting approved the resolution to acquire 51% equity of Kunming Huarun Shenghuo Pharmaceutical from China Resources Sanjiu for RMB 1.791 billion.昆药集团临时股东大会通过决议，批准以17.91亿元收购华润三九持有的昆明华润圣火药业51%股权。
2024-07-29China Resources Sanjiu and its subsidiary Kunming Pharmaceutical Group (KPC) jointly build the 'KPC 1381' and '777' brands, leveraging Sanjiu's brand-building, channel, and terminal advantages to empower KPC's channel coverage, terminal control, and product competitiveness.华润三九协同昆药集团共同打造“昆中药1381”、“777”品牌，借助三九商道体系和终端覆盖等优势赋能昆药渠道覆盖率、终端掌控力和产品竞争力。
2024-07-29China Resources Sanjiu stated that after becoming the controlling shareholder of Kunming Pharmaceutical Group, the two parties are steadily advancing integration through a 100-day, one-year, three-year mechanism, with KPC's strategic goal set as 'leader in silver-health industry, leader in premium Chinese medicine, and leader in elderly health/chronic disease management'.华润三九成为昆药集团控股股东后，双方按百日融合、一年融合、三年融合机制稳步推进融合，昆药集团战略目标定为“银发健康产业引领者、精品国药领先者、老龄健康/慢病管理领域领导者”。
2024-07-29Kunming Pharmaceutical Group released its five-year (2024-2028) strategic plan, focusing on premium Chinese medicine and elderly health/chronic disease management, with key platforms built around the Sanqi (Panax notoginseng) series products and the 'KPC 1381' series.昆药集团发布未来五年（2024-2028年）发展战略规划，聚焦精品国药、老龄健康-慢病管理两大核心业务，重点打造三七系列产品及“昆中药1381”系列平台。
2024-11-21China Resources Sanjiu agreed to sell 51% equity of China Resources Shenghuo to Kunming Pharmaceutical (600422.SH) for RMB 1.791 billion, to resolve product competition in Xuesaitong soft capsules and optimize the Sanqi (Panax notoginseng) industry chain.华润三九与昆药集团订立股权转让协议，以17.91亿元出售华润圣火51%权益，解决血塞通软胶囊同业竞争问题，优化三七产业链布局。
2024-12-20Completed transfer of 51% equity in Kunming Sanji Holy Fire (昆明华润圣火药业) to Kunming Pharma (昆药集团) to resolve horizontal competition; industrial and commercial registration done.完成向昆药集团转让昆明华润圣火药业有限公司51%股权的工商变更登记，以解决同业竞争。
2025-02-05China Resources Sanjiy completed the industrial and commercial registration for the transfer of 51% equity in China Resources Shenghuo (华润圣火) on December 20, 2024, with proceeds of RMB 1.9 billion to be received in installments.华润三九于2024年12月20日完成华润圣火51%股权转让的工商变更登记手续，转让价款19亿元分期收取。
2025-07-24Kunming Pharma (昆药集团) launched oral care products containing notoginseng (三七) ingredients, such as toothpaste, under its big health product line.昆药集团在大健康产品线中推出了含有三七成分的口腔护理产品，如牙膏等。
2025-08-20Kunming Pharma (昆药集团), a subsidiary of China Resources Sanjiu, provided a CNY 10 million guarantee to its wholly-owned subsidiary China Resources Sanjiu (Youyang) Pharmaceutical, whose asset-liability ratio is 104.86%.华润三九控股子公司昆药集团为其全资子公司华润三九（酉阳）制药有限公司提供1000万元担保，被担保方资产负债率为104.86%。
2025-09-08Kunming Pharma Group, a subsidiary of China Resources Sanjiu (28.05% stake), issued a tender for a sales promotion support project with a budget of RMB 3.00 million.华润三九持股28.05%的子公司昆药集团发布动销支持项目招标公告，预算金额300.00万元。
2025-10-26Analysis indicated that China Resources Sanjiu's revenue growth without profit growth in Q3 2025 was mainly due to the significant performance decline of its subsidiary Kunming Pharmaceutical Group, whose Q3 revenue fell 30.19% YoY and net profit fell 59.03% YoY.分析指出，华润三九2025年第三季度增收不增利主要因子公司昆药集团业绩显著下滑，其第三季度营业收入同比下降30.19%，归母净利润同比下降59.03%。
2025-12-22Controlled subsidiary Kunming Pharma provided RMB 10 million in guarantees to two wholly-owned Sun-subsidiaries (Beck-Norton (Zhejiang) and Kunming Pharma Commercial (Zhaotong)), within the approved 2025 guarantee plan.控股子公司昆药集团为其两家全资孙公司（贝克诺顿浙江、昆药商业昭通）提供合计1,000万元担保，在2025年度担保计划额度内。
2026-01-05Kunming Pharma (600422) chairman Wu Wenduo resigned; Yu Xiang (VP of China Resources Sanjiu) appointed as new chairman.昆药集团董事长吴文多辞职；华润三九副总裁喻翔被推举为新任董事长。
2026-04-20Kunming Pharma (KunYao) is restructuring channels and building brands '777' and 'Kunzhongyao 1381' to pivot to retail and silver economy, but brand system still needs time.昆药集团正在深入推动渠道重构和品牌建设，推出“777”和“昆中药1381”两大品牌，向零售端和银发经济转型，但品牌体系构建仍需时间。
2026-05-20China Resources Sanjiu reiterated its commitment to resolve horizontal competition with Kunming Pharma Group's commercial distribution business within 5 years, currently solidifying business foundation.华润三九重申承诺在5年内解决与昆药集团医药商业流通业务的同业竞争问题，目前正在夯实业务基础。
2026-06-05Subsidiary Kunming Pharma (Kunji Group) plans to apply for registration of up to RMB 1 billion in debt financing instruments on the interbank bond market.控股子公司昆药集团拟申请注册发行不超过10亿元的银行间债券市场非金融企业债务融资工具。
2026-06-15Brand transition strategy for Lixuwang (理洫王): medical channel switched to '777 Lixuwang' packaging, retail channel still uses '999 Lixuwang', with gradual update to '777 Lixuwang'.理洫王实行渠道差异化品牌过渡策略：医疗端已完成“777理洫王”包装切换，零售端仍以“999理洫王”为主，后续逐步更新为“777理洫王”。
2026-06-29Kunji Group (600422) senior VP Liu Junfeng resigned for personal reasons; Liang Huacheng appointed as VP (previously CFO of Boya Bio and finance roles at China Resources Sanjiu).昆药集团高级副总裁刘军锋因个人原因辞职，聘任梁化成为副总裁（曾任博雅生物财务总监、华润三九抗感染事业部财务总监等）。
CHC brand strategy & OTC portfolioCHC品牌战略与OTC产品线
8 · 2024-02-07 → 2025-09-09
▾
Execution of the '1+N' brand strategy, launches of new OTC products like Ibuprofen Suspension, and management of the core consumer health portfolio.执行'1+N'品牌战略，推出布洛芬混悬液等新OTC产品，管理核心消费健康产品组合。
2024-02-07Company reiterated '1+N' brand strategy, with '1' being 999 family standby medicines and 'N' including Aonuo (children's calcium), Tianhe (orthopedics), Yishanfu (liver disease), and Kunzhongyao 1381 (traditional Chinese medicine) acquired via Kunyao Group.公司重申'1+N'品牌战略，'1'为999家庭常备用药，'N'包括澳诺（儿童补钙）、天和（骨科）、易善复（肝病）及通过昆药收购的昆中药1381。
2024-02-07Company launched 999 Ibuprofen Suspension (ibuprofen suspension) under CHC business, targeting self-medication needs in prevention-treatment-rehabilitation.公司CHC业务推出999布洛芬混悬液，覆盖预防-治疗-康复全领域自我诊疗需求。
2024-04-12China Resources Sanjiu stated on the investor interactive platform that due to rising costs, it will consider moderate small price increases for core OTC varieties to cover cost increases, while fully considering consumer/patient acceptance.华润三九在互动平台表示，由于成本上涨，公司OTC核心品种会考虑适度小幅提价，覆盖成本上涨影响，并充分考虑消费者/患者接受程度。
2024-05-15Investor relations record revealed that oseltamivir phosphate capsules (flu product) have been approved and will launch soon; 999 Ibuprofen Suspension already launched.投资者关系记录显示，磷酸奥司他韦胶囊（流感产品）已获批即将上市，999布洛芬混悬液已上市。
2024-05-17Confirmed cooperation with Sanofi includes agency for liver-protecting product Yishanfu and a joint venture for pediatric and gynecological OTC products.确认与赛诺菲的合作包括代理保肝产品易善复，以及合资生产儿科和妇科非处方药。
2025-01-23China Resources Sanjiu responded that its traditional Chinese medicine business still accounts for a relatively high proportion of total revenue, while its CHC business includes both TCM and chemical drugs.华润三九回应称中药业务在公司业务中占比较高，CHC业务产品组合包括中药及化药。
2025-07-10CEO Qiu Huawei (邱华伟) outlined strategy: CHC business to focus on OTC in respiratory, dermatology, and gastric areas; professional brands and health to target pediatrics and gynecology; synergy with Tasly to enrich R&D pipeline and strengthen medical-end brand influence.董事长邱华伟阐述战略：CHC业务聚焦OTC呼吸、皮肤、胃药三大领域；专业品牌和大健康关注儿科、妇科；与天士力协同赋能，丰富研发管线，强化医疗端品牌影响力。
2025-09-09At the 18th Health Industry Ecosystem Conference (2025 Xipu Hui), Chairman Qiu Huawei outlined the company's transformation from single-product hits to a '1+N' brand system covering cold, gastrointestinal, skin, orthopedics, and pediatrics, and the integration of Kunming Pharma and Tasly Group to build dual wings in silver-health and innovative Chinese medicine.华润三九董事长邱华伟在第十八届健康产业生态大会（2025西普会）上阐述企业从单品爆款向覆盖感冒、胃肠、皮肤、骨科、儿科等场景的“1+N”品牌体系转型，并融合昆药集团、天士力集团打造银发健康与中药创新药双翼。
New drug approvals (chemical generics & TCM)新药获批（化药仿制药与中药）
5 · 2024-02-21 → 2025-11-13
▾
A steady stream of Drug Registration Certificates for chemical generics and new TCM drugs, including Terbinafine Spray, Glucosamine Sulfate, and Oseltamivir.持续获得化药仿制药和中药新药注册证书，包括盐酸特比萘芬喷雾剂、硫酸氨基葡萄糖和奥司他韦等。
2024-02-21China Resources Sanjiu received NMPA approval for Terbinafine Hydrochloride Spray (30ml, 10mg/g), a chemical Category 4 generic drug, the second domestic company to pass consistency evaluation.华润三九盐酸特比萘芬喷雾剂（30ml，10mg/g）获国家药监局批准上市，化药4类，国内第二家通过一致性评价。
2024-03-01China Resources Sanjiu obtained Drug Registration Certificate for Terbinafine Hydrochloride Spray (30ml/bottle, 10mg/g), a Category 4 chemical drug deemed to have passed generic consistency evaluation, becoming the second domestic company to do so.华润三九获得盐酸特比萘芬喷雾剂（30ml/瓶，10mg/g）药品注册证书，化药4类视同通过一致性评价，成为国内第二家通过企业。
2024-10-21Glucosamine Sulfate Capsules (0.25g/0.314g) approved by NMPA as a Category 4 chemical generic drug for osteoarthritis, passing consistency evaluation.硫酸氨基葡萄糖胶囊（0.25克/0.314克）获国家药监局批准上市，为化药4类仿制药，视同通过一致性评价，用于骨关节炎。
2025-03-12China Resources Sanjiu disclosed that in 2024 it obtained 6 Drug Registration Certificates, including for oseltamivir phosphate dry suspension, terbinafine hydrochloride spray, and sodium hyaluronate eye drops.华润三九披露2024年获得6个《药品注册证书》，包括磷酸奥司他韦干混悬剂、盐酸特比萘芬喷雾剂、玻璃酸钠滴眼液等。
2025-11-13China Resources Sanjiu's generic drug Crisaborole Ointment (Category 4) was approved for production and passed consistency evaluation; year-to-date, the company has obtained 2 ancient classic prescription compound preparations and 10 generic approvals, bringing total generic approvals to 65.华润三九申报的4类仿制药克立硼罗软膏获批生产并视同过评；今年以来公司获得2款古代经典名方复方制剂，10个品种获批生产并视同过评，总过评品种数增至65个。
Subsidiary guarantees & financing子公司担保与融资
7 · 2024-02-22 → 2026-03-21
▾
Provision of guarantees for subsidiary bank financing, primarily for Kunming Pharma and its sub-subsidiaries.为子公司（主要是昆药集团及其下属公司）的银行融资提供担保。
2024-02-22Controlled subsidiary Kunyao Group provided a RMB 10 million guarantee to its wholly-owned subsidiary Beijing Huafang Ketai Pharmaceutical Co., Ltd., with cumulative guarantees reaching RMB 20 million.控股子公司昆药集团为其全资子公司北京华方科泰医药有限公司提供1000万元担保，累计担保余额2000万元。
2024-08-19CR Sanjiu provided a guarantee of RMB 7.65 million for its subsidiary Kunming Pharma's controlled entity Dali Huirui Pharmaceutical, with cumulative guarantee balance reaching RMB 29.85 million.华润三九为子公司昆药集团下属控股公司大理辉睿药业提供765万元担保，累计担保余额达2985万元。
2024-10-22Kunming Pharma (subsidiary) provided guarantees totaling RMB 49.5 million to five distributors including Qujing Kangqiao, Dali Huirui, etc., with cumulative guarantee balance of RMB 106.35 million.昆药集团为曲靖康桥、大理辉睿等五家经销商提供合计4950万元担保，累计担保余额为10635万元。
2025-03-25China Resources Sanjiu's board approved a guarantee plan for its subsidiary Kunming Pharma Group, providing up to 456.15 million yuan in joint liability guarantees for bank financing in 2025.华润三九董事会审议通过控股子公司昆药集团2025年度担保计划，提供不超过4.5615亿元连带责任担保。
2025-06-25Controlled subsidiary Kunyao Group provided total 12.5 million yuan in guarantee for two sub-subsidiaries: 7.5 million yuan for Qujing Kangqiao Medical (60% owned) and 5 million yuan for Zhaotong Medical, both maturing June 2026.控股子公司昆药集团为两家孙公司提供合计1250万元融资担保：为持股60%的曲靖康桥医药提供750万元，为全资孙公司昭通医药提供500万元，担保期限至2026年6月。
2025-10-24China Resources Sanjiu announced progress on guarantee matters for its controlled subsidiary Kunming Pharmaceutical Group, with total guarantees not exceeding 456.15 million yuan for bank financing in 2025.华润三九公告控股子公司昆药集团担保事项进展，2025年度担保总额不超过4.5615亿元。
2026-03-21Board approved 2026 guarantee plan for subsidiary Kunyao Group.董事会审议通过控股子公司昆药集团2026年度担保计划。
Financial operations & investments财务运营与投资
5 · 2024-03-22 → 2026-08-21
▾
Asset impairments, fund investments in wealth management products, and related-party financial cooperation.资产减值、闲置资金理财投资及关联方金融合作。
2024-03-22China Resources Sanjiu disclosed asset impairment provisions of approximately RMB 326 million for 2023, reducing 2023 profit by about RMB 207 million.华润三九披露2023年计提各项资产减值准备约3.26亿元，减少2023年度利润约2.07亿元。
2024-09-27China Resources Sanjiu announced it will use up to 7 billion yuan of its own funds to invest in bank wealth management products (excluding Zhuhai China Resources Bank), with a rolling limit and a maximum term of six months.华润三九公告拟使用合计不超过70亿元自有资金投资银行理财产品（不含珠海华润银行），资金可滚动使用，单笔期限不超过六个月。
2024-10-25Disclosed plan to invest up to RMB 7 billion of self-owned funds in bank wealth management products (excluding Zhuhai China Resources Bank).披露拟以合计不超过70亿元自有资金投资银行理财产品（不含珠海华润银行）。
2026-03-21Board approved 2025 asset impairment provision of 338.11 million yuan, reducing profit before tax by 121.69 million yuan.董事会审议通过2025年度计提资产减值准备3.38亿元，减少利润总额1.22亿元。
2026-08-21Board approved plan to invest up to RMB 10bn of idle自有 funds in bank wealth management products (R2 or below fixed-income non-guaranteed floating products and structured deposits), with Kunming Pharma quota RMB 2bn and Tasly Pharma quota RMB 4bn; valid until 2027-09-10, pending shareholder approval.董事会审议通过拟使用合计不超过100亿元自有资金投资银行理财产品（R2及以下固定收益类非保本浮动收益型及结构性存款），其中昆药集团额度不超过20亿元、天士力额度不超过40亿元，期限至2027年9月10日，尚需股东会审议。
Chenzhou South China manufacturing center郴州华南制造中心
1 · 2024-03-23
▾
Construction, startup, and smart-manufacturing ramp-up of the new Chenzhou production base, a key hub for capacity expansion.新建郴州生产基地的建设、投产和智能制造升级，是产能扩张的关键枢纽。
2024-03-23China Resources Sanjiu officially inaugurated its South China production and manufacturing center in Chenzhou, and Shenzhen Jiuxing Printing and Packaging Group signed an agreement to settle in Chenzhou Economic Development Zone.华润三九华南区生产制造中心正式授牌，深圳九星印刷包装集团签约入驻郴州经开区。
M&A strategy & target denials并购战略与否认收购
9 · 2024-04-02 → 2025-04-08
▾
Articulation of the M&A strategy focused on CHC brands and prescription drug innovation, alongside denials of potential acquisitions of specific companies.阐述聚焦CHC品牌和处方药创新的并购战略，同时否认对特定公司的潜在收购。
2024-04-02China Resources Sanjiu stated in an institutional survey that it plans to increase M&A efforts, focusing on mature CHC businesses with certain scale profits and innovative opportunities in prescription drugs, with flexible methods including controlling stakes, product rights introduction, or equity participation.华润三九在机构调研中表示，计划加大并购力度，CHC业务关注有一定规模利润的成熟企业，处方药业务倾向于创新型业务机会，投资方式包括控股、产品权益引进或参股等。
2024-04-08China Resources Sanjiu stated that M&A will focus on CHC business around new brands, technologies, and products, and prescription drugs around the '3+N' areas (oncology, respiratory, digestive, and specialty pipelines).华润三九表示，并购将围绕CHC业务布局新品牌、新技术、新产品，处方药领域围绕“3+N”（肿瘤、呼吸、消化及特色管线）推动。
2024-08-19CR Sanjiu stated it has no plans to acquire Huanqiu Print (环球印务, 002799), and will continue to seek targets aligned with its strategic development.华润三九表示未考虑收购环球印务（002799），将继续围绕战略发展方向寻找合作标的。
2024-10-09Company expects 2024 revenue to exceed industry average and strives for double-digit growth; M&A focus on consumer health new brands, technologies, products, and prescription drug '3+N' strategy.公司预计2024年营业收入将超越行业平均增速，力争实现双位数增长；并购聚焦于消费健康领域的新品牌、新技术、新产品以及处方药的“3+N”战略方向。
2024-10-15Company stated it has no plans to acquire Sinopharm-related entities.公司表示无收购国药系相关计划。
2024-12-11Company stated it has no equity cooperation with Sailhero (塞力医疗, 603716).公司表示目前与塞力医疗（603716）无股权合作。
2025-01-07China Resources Sanjiu stated it has no plan to merge with Taiji Group (600129).华润三九表示无合并太极集团（600129）的相关计划。
2025-04-03China Resources Sanjiu stated it will continue the dual-drive of internal growth and external expansion, increasing M&A and BD efforts, focusing on brand assets in CHC and expanding innovation in prescription drug '3+N' fields.华润三九表示将继续以内涵式加外延式双轮驱动，加大并购重组和BD举措，在CHC核心业务方向关注品牌资产，处方药围绕“3+N”领域拓展创新。
2025-04-08China Resources Sanjiu denied any plan to acquire King's (Kyoto Nianci'an), stating it has no related plans.华润三九否认有并购京都念慈菴的计划，表示公司无相关计划。
Eisai China 'Meineng' project卫材中国'美能'项目
1 · 2024-04-08
▾
Tripartite cooperation with Eisai China and China Resources Pharmaceutical Commercial on the 'Meineng' project spanning medical, innovation, and patient management.与卫材中国、华润医药商业就'美能'项目开展三方合作，涵盖医疗、创新和患者管理。
2024-04-08Eisai China (卫材中国) signed a cooperation agreement with China Resources Pharmaceutical Commercial Group (华润医药商业) and China Resources Sanjiu for the 'Meineng' (美能) project, covering traditional medical, innovative projects, patient management, and internet healthcare.卫材（中国）药业与华润医药商业集团及华润三九签订美能项目合作协议，涉及传统医疗、创新项目、患者管理和互联网医疗健康等领域。
Dividend policy & shareholder returns分红政策与股东回报
11 · 2024-04-08 → 2026-08-21
▾
Commitment to increased dividend frequency and stable payout ratio, including special interim dividends and the 'Quality & Return Dual Enhancement' plan.承诺提高分红频率和稳定派息率，包括特别中期股息和'质量回报双提升'计划。
2024-04-08China Resources Sanjiu announced a dividend plan for 2023: RMB 15 cash per 10 shares (total RMB 1.482 billion, 51.96% of net profit), plus a capital reserve increase of 3 shares per 10 shares.华润三九公布2023年权益分派方案：每10股派送现金15元（合计14.82亿元，占净利润51.96%），同时每10股转增3股。
2024-06-05China Resources Sanjiu announced 2023 annual profit distribution: cash dividend of RMB 15.00 per 10 shares (total RMB 1.482 billion, 51.96% of net profit) and capital reserve capitalization of 3 shares per 10 shares, with record date June 13 and ex-dividend date June 14.华润三九公布2023年度权益分派：每10股派15元现金（合计14.82亿元，占归母净利润51.96%）并每10股转增3股，股权登记日6月13日，除权除息日6月14日。
2024-10-25Proposed 2024 first-three-quarters profit distribution: RMB 10.00 cash dividend per 10 shares, totaling RMB 1.284 billion, to be voted at the 6th extraordinary general meeting on Nov 11.2024年前三季度利润分配预案：每10股派发现金红利10.00元，合计12.84亿元，将于11月11日股东大会审议。
2024-11-21China Resources Sanjiu announced a cash dividend of RMB 10.00 per 10 shares for the first three quarters of 2024, totaling RMB 1.284 billion, representing 43.39% of net profit; ex-dividend date is November 29, 2024.华润三九宣布2024年前三季度权益分派：每10股派发现金红利10元，合计12.84亿元，占归母净利润43.39%，除权除息日为2024年11月29日。
2025-01-23China Resources Sanjiu confirmed it has implemented a 2024 first-three-quarters dividend distribution and will continue to increase dividend frequency, including pre-Spring Festival dividends, under its 'Quality & Return Dual Enhancement' action plan.华润三九确认已实施2024年前三季度分红，并将按照“质量回报双提升”行动方案增加分红频次，包括春节前分红。
2025-06-20Company stated it will continue dual internal and external growth, focusing on brand assets and innovation; expects dividend payout ratio to remain stable at 40%-50%.公司表示将继续以内生式与外延式双轮驱动，聚焦品牌资产和创新领域；预计未来分红比例将稳定在40%-50%。
2025-07-23Confirmed stable dividend payout ratio of 40%-50% and stated it continues to watch for quality M&A opportunities aligned with strategic direction.确认维持40%-50%的稳定分红比例，并表示持续关注符合战略方向的优质并购整合机会。
2025-10-14China Resources Sanjiu announced that in 2024 it distributed total dividends of 1.695 billion yuan (50.34% of net profit), and in H1 2025 it paid a cash dividend of 4.5 yuan per 10 shares (total ~750 million yuan), marking its first semi-annual dividend.华润三九宣布2024年合计分红总额16.95亿元（占净利润50.34%），2025年上半年首次进行半年度分红，每10股派发现金红利4.5元（含税），总额近7.5亿元。
2026-03-202025 annual report proposes total cash dividend of 1.731 billion yuan for the year, representing 50.59% of net profit.2025年年报提议全年累计现金分红17.31亿元，占净利润50.59%。
2026-05-29China Resources Sanjiu announced that its cumulative cash dividends for 2025 totaled approximately 1.731 billion yuan, representing 50.59% of net profit attributable to parent, and cumulative dividends since listing exceeded 10 billion yuan.华润三九宣布2025年度累计现金分红约17.31亿元，占归母净利润的50.59%，上市以来累计现金分红超100亿元。
2026-08-21H1 2026 results: revenue RMB 15.014bn (+1.37% yoy); net profit attributable to shareholders RMB 1.671bn (-7.96% yoy); non-GAAP net profit RMB 1.597bn (-5.93% yoy); interim dividend RMB 4.15 per 10 shares (total RMB 691m, 41.34% payout).2026年半年报：营业收入150.14亿元（同比+1.37%）；归母净利润16.71亿元（同比-7.96%）；扣非归母净利润15.97亿元（同比-5.93%）；中期每10股派现4.15元（合计6.91亿元，派息率41.34%）。
Classic famous formula (ancient classic) approvals经典名方获批
13 · 2024-05-07 → 2026-07-30
▾
A stream of approvals for ancient classic formula granules and pastes, including Linggui Zhugan, Wenjing Tang, Shaoyao Gancao, and others, establishing leadership in this category.连续获批经典名方颗粒和膏剂，包括苓桂术甘、温经汤、芍药甘草等，确立该领域领先地位。
2024-05-07China Resources Sanjiu's first classic traditional Chinese medicine formula, Linggui Zhugan Granules, received marketing approval.华润三九研发的首个中药经典名方——苓桂术甘颗粒获批上市。
2024-11-28Two China Resources Sanjiu products were newly included in the 2024 National Medical Insurance Catalog via negotiation: Wenjing Tang Granules (ancient classic formula) and Cefobiprole Sodium for Injection (5th-generation cephalosporin, first in China).华润三九两款药品通过谈判首次纳入2024年国家医保目录：温经汤颗粒（古代经典名方）和注射用头孢比罗酯钠（国内首个第五代头孢菌素）。
2024-11-28China Resources Sanjiu's self-developed ancient classic formula Shaoyao Gancao Granules received NMPA approval for marketing, becoming the company's third such approved product (after Linggui Zhugan and Wenjing Tang), maintaining industry leadership.华润三九自研古代经典名方中药复方制剂芍药甘草颗粒获国家药监局批准上市，成为公司第三个获批的3.1类经典名方（继苓桂术甘颗粒、温经汤颗粒后），保持行业领先。
2025-05-30China Resources Sanjiu has obtained Drug Registration Certificates for 4 classic famous formulas: Wengjingtang granules, Lingguizhugan granules, Shaoyaogancao granules, and Yiqiqingfei granules.华润三九已获得温经汤颗粒、苓桂术甘颗粒、芍药甘草颗粒、益气清肺颗粒4个经典名方《药品注册证书》。
2025-12-29Anhui China Resources Jinchan's Banxia Baizhu Tianma Tang Granules (classic formula) obtained approval as the first domestic manufacturer; this is China Resources Sanjiu's 5th approved ancient classic formula.安徽华润金蟾药业的半夏白术天麻汤颗粒获批，为国内首家；这是华润三九第5款获批上市的古代经典名方。
2026-02-10China Resources Sanjiu's ancient classic prescription granule 'Taohe Chengqi Decoction Granules' (桃核承气汤颗粒) obtained NMPA approval for marketing (approval number: Guoyao Zhunzi C20260003), derived from Zhang Zhongjing's 'Treatise on Febrile Diseases'.华润三九的古代经典名方中药复方制剂'桃核承气汤颗粒'获国家药监局批准上市（批准文号：国药准字C20260003），源自东汉张仲景《伤寒论》。
2026-06-11China NMPA approved the first paste formulation of the ancient classic formula Dajianzhong Decoction (Dajianzhong Tang Gao), a Category 3.1 new Chinese medicine, for market launch.国家药监局批准华润三九申报的中药3.1类新药大建中汤膏（首个膏剂类古代经典名方中药复方制剂）首家获批上市。
2026-06-24Completed procurement for pharmacoeconomics and budget impact analysis of Taohe Chengqi Tang Granules (桃核承气汤颗粒); supplier is Nanjing Dele Pharmaceutical Technology Co., Ltd.桃核承气汤颗粒药物经济学及预算影响分析研究项目采购完成，成交供应商为南京得乐医药科技有限公司。
2026-06-24Completed procurement for pharmacoeconomics and budget impact analysis of Dajianzhong Tang Gao (大建中汤膏); supplier is Nanjing Dele Pharmaceutical Technology Co., Ltd.大建中汤膏药物经济学及预算影响分析研究项目采购完成，成交供应商为南京得乐医药科技有限公司。
2026-06-24Completed procurement for consultation and advisory services for Taohe Chengqi Tang Granules (桃核承气汤颗粒); supplier is Nanjing Boerze Trading Co., Ltd.桃核承气汤颗粒论证与咨询服务项目采购完成，成交供应商为南京博尔泽贸易有限公司。
2026-06-24Completed procurement for consultation and advisory services for Dajianzhong Tang Gao (大建中汤膏); supplier is Nanjing Boerze Trading Co., Ltd.大建中汤膏论证与咨询服务项目采购完成，成交供应商为南京博尔泽贸易有限公司。
2026-06-24Completed procurement for pharmacoeconomics and budget impact analysis of Banxia Baizhu Tianma Tang Granules (半夏白术天麻汤颗粒); supplier is Nanjing Dele Pharmaceutical Technology Co., Ltd.半夏白术天麻汤颗粒药物经济学研究及预算影响分析项目采购完成，成交供应商为南京得乐医药科技有限公司。
2026-07-30Wenjing Tang Granules (温经汤颗粒) application accepted by CDE, acceptance number CYZB2603775.温经汤颗粒申请获国家药监局药审中心受理，受理号CYZB2603775。
China Resources Power new energy cooperation华润电力新能源合作
3 · 2024-05-14 → 2026-03-21
▾
Ongoing 'medicine-light complementary' photovoltaic projects and new energy power generation agreements with China Resources Power.与华润电力持续开展'药光互补'光伏项目及新能源发电合作。
2024-05-14Signed a new energy project cooperation agreement with China Resources Power for 'medicine-light complementary' photovoltaic projects, with 2024 transaction cap of RMB 200 million.与华润电力签署新能源发电项目合作协议，涉及‘药光互补’光伏项目，2024年交易上限2亿元。
2025-05-14China Resources Sanjiu signed a 'New Energy Power Generation Project Cooperation Agreement' with China Resources Power (00836.HK) for 2025-2027, with annual transaction cap of 200 million yuan and total cap of 600 million yuan, covering land remediation services via TCM planting on solar projects.华润三九与华润电力（00836.HK）签署2025-2027年《新能源发电项目合作协议》，年度交易上限2亿元，总交易上限6亿元，通过在光伏项目上种植中药材提供土地综合治理服务。
2026-03-21Independent directors' report reveals related-party transactions: cooperation with China Resources Power on new energy projects (total up to 600 million yuan over 3 years), 2026 daily related-party transactions up to 4.944 billion yuan, and subsidiary Chenzhou Sanjiu energy supply agreement (up to 99 million yuan over 3 years).独立董事报告披露关联交易：与华润电力新能源项目合作（三年不超6亿元）、2026年度日常关联交易不超49.44亿元、子公司郴州三九能源供应协议（三年不超9900万元）。
2021 Restricted Stock Incentive Plan2021年限制性股票激励计划
12 · 2024-05-27 → 2026-04-20
▾
Administration of the 2021 equity incentive plan, including share unlocks, repurchases, cancellations due to unmet performance, and adjustments.管理2021年股权激励计划，包括股份解锁、回购、因业绩未达标而注销及调整。
2024-05-27263.03万股 restricted shares from 2021 equity incentive plan became tradable on May 27, 2024, representing 0.27% of total shares.2021年限制性股票激励计划首次授予部分263.03万股于2024年5月27日解禁上市，占总股本0.27%。
2024-08-30CR Sanjiu's 17th board meeting approved the proposal to repurchase and cancel some restricted shares under the 2021 restricted stock incentive plan.华润三九第十七次董事会会议审议通过了关于2021年限制性股票激励计划回购注销部分限制性股票的议案。
2024-09-18China Resources Sanjiu held an EGM approving the repurchase and cancellation of 26,781 restricted shares from three ineligible incentive plan participants.华润三九召开临时股东大会，批准对3名不符合条件的激励对象持有的2.6781万股限制性股票进行回购注销。
2025-05-14China Resources Sanjiu's board and supervisory board approved adjustments to the 2021 restricted stock incentive plan (grant quantity and price) and the repurchase and cancellation of some restricted shares.华润三九董事会和监事会审议通过调整2021年限制性股票激励计划授予数量和价格，以及回购注销部分限制性股票的议案。
2025-05-22China Resources Sanjiu released 3,172,332 restricted shares (0.25% of total shares) for the second unlocking period of the 2021 restricted stock incentive plan, involving 240 participants.华润三九2021年限制性股票激励计划第二个解锁期解除限售317.2332万股（占总股本0.25%），涉及240名激励对象。
2025-06-16Board of directors approved proposals to repurchase and cancel some restricted shares under the 2021 restricted stock incentive plan, and to cancel the third unlocking tranche due to unmet conditions; a special general meeting will be held on July 7, 2025.董事会审议通过了关于2021年限制性股票激励计划回购注销部分限制性股票及第三个解锁期解锁条件未成就回购注销的议案；将于2025年7月7日召开临时股东大会。
2025-07-07Fourth extraordinary general meeting of shareholders in 2025 approved two restricted stock incentive plan proposals, including buyback and cancellation of shares for 17 departing/underperforming grantees (585,985 shares) and for unmet third vesting conditions (4,747,942 shares), reducing total shares from 1.670 billion to 1.664 billion.2025年第四次临时股东会审议通过两项限制性股票激励计划议案，包括因17名激励对象离职/绩效未达标回购注销58.5985万股，以及第三个解锁期条件未成就回购注销474.7942万股，总股本从16.70亿股减少至16.64亿股。
2025-08-14China Resources Sanjiu's board approved the vesting of the second tranche of the 2021 restricted stock incentive plan (reserved portion): 640,058 shares for 123 employees, and repurchase of 36,505 shares from 6 ineligible employees.华润三九董事会审议通过2021年限制性股票激励计划预留授予部分第二个解锁期解锁条件成就，123名激励对象可解锁64.0058万股；同时回购注销6名不符合条件激励对象持有的3.6505万股。
2025-09-02China Resources Sanjiu held its 5th extraordinary general meeting of 2025, approving the 2025 semi-annual profit distribution plan, the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan, and the reappointment of the 2025 annual auditor.华润三九召开2025年第五次临时股东会，审议通过2025年半年度利润分配预案、回购注销部分限制性股票及续聘2025年审计机构议案。
2025-09-10China Resources Sanjiu completed the repurchase and cancellation of 5,333,927 restricted shares (0.32% of total shares) under the 2021 restricted stock incentive plan, using RMB 34.5514 million of self-owned funds. This included 585,985 shares from 17 former grantees (due to resignation, retirement, or unmet performance) and 4,747,942 shares from 363 grantees because the third vesting period performance target was not achieved.华润三九完成2021年限制性股票激励计划部分回购注销，共注销533.3927万股（占总股本0.32%），回购资金3455.14万元。其中17名原激励对象因离职、退休或绩效未达标回购58.5985万股；因第三个解锁期业绩条件未成就，对363名激励对象回购474.7942万股。
2026-03-21Independent directors' report notes that the 2021 restricted stock incentive plan's third unlocking period was not achieved due to performance failure, leading to repurchase and cancellation of shares.独立董事报告提及2021年限制性股票激励计划第三个解锁期因业绩未达标未成就，已回购注销。
2026-04-20Chairman Qiu Huawei's share reduction from 300,000+ to 215,200 shares due to repurchase and cancellation of restricted stock.董事长邱华伟持股从30多万股减少至21.52万股，系因回购注销相应限制性股票。
Industry honors & rankings行业荣誉与排名
8 · 2024-06-13 → 2025-05-15
▾
Recognition as a Manufacturing Single Champion, top rankings in pharmaceutical competitiveness lists, and national science and technology awards.被评为制造业单项冠军，在医药竞争力榜单中名列前茅，并获得国家科学技术奖。
2024-06-13China Resources Sanjiu was awarded the national 'Manufacturing单项冠军' (Manufacturing Single Champion) certificate by the Ministry of Industry and Information Technology for its leadership in the Chinese patent medicine production segment.华润三九获工信部颁发国家级“制造业单项冠军”证书，认可其中成药生产细分领域的领先地位。
2024-06-25China Resources Sanjiu won the 2023 National Science and Technology Progress Award (Second Class) for its participation in the project 'Construction and Demonstration Application of Ecological Planting Theory and Technology System for Chinese Medicinal Materials', using wild chrysanthemum (raw material for 999 Ganmaoling) as a model.华润三九参与的《中药材生态种植理论和技术体系的构建及示范应用》项目荣获2023年度国家科学技术进步奖二等奖，以999感冒灵原料野菊花为示范。
2024-09-27China Resources Sanjiu ranked first in the '2024 China Pharmaceutical Listed Company Competitiveness Top 20', becoming the first TCM company to top the list in nearly a decade.华润三九在'2024中国医药上市公司竞争力20强'中位列第一，成为近十年来首登榜首的中药企业。
2024-10-09China Resources Sanjiu ranked first in the '2024 China Listed Pharmaceutical Companies Competitiveness Top 20', becoming the first TCM company to top the list in nearly a decade.华润三九在“2024中国医药上市公司竞争力20强”中位列第一，成为近十年来首家登顶该榜单的中药企业。
2024-10-21Project 'Construction and Promotion of the 'Human Use Experience' Technical System for Traditional Chinese Medicine' won the first prize of Guangdong Provincial Science and Technology Progress Award, the only TCM first prize.项目《中药“人用经验”技术体系构建与推广应用》荣获广东省科技进步奖一等奖，是本届中医药领域唯一一等奖。
2025-02-27China Resources Sanjiu disclosed that its project 'Construction and Demonstration Application of Ecological Planting Theory and Technology System for Chinese Medicinal Materials' won the second prize of the National Science and Technology Progress Award in 2024.华润三九披露，其参与的《中药材生态种植理论和技术体系的构建及示范应用》项目荣获2024年国家科学技术进步奖二等奖。
2025-03-28China Resources Sanjiu disclosed that its project 'Construction and Demonstration Application of Ecological Planting Theory and Technology System for Chinese Medicinal Materials' won the second prize of the National Science and Technology Progress Award in 2024.华润三九参与的《中药材生态种植理论和技术体系的构建及示范应用》项目荣获2024年国家科学技术进步奖二等奖。
2025-05-15China Resources Sanjiu's project 'Construction and Demonstration Application of Ecological Planting Theory and Technology System for Chinese Medicinal Materials' won the Second Prize of the National Science and Technology Progress Award; independently bred new chrysanthemum variety planted on 200,000 mu with total output value over 150 million yuan.华润三九参与的《中药材生态种植理论和技术体系的构建及示范应用》项目获国家科学技术进步二等奖；自主选育的野菊花新品种推广面积20万亩，总产值超1.5亿元。
Consumer complaints & quality disputes消费者投诉与质量纠纷
4 · 2024-06-14 → 2026-01-13
▾
Handling of consumer complaints filed on the 12315 platform regarding product quality issues.处理在12315平台上提交的关于产品质量问题的消费者投诉。
2024-06-14Two consumer complaints were filed against China Resources Sanjiu subsidiaries: one against Huarun Sanjiu (Nanchang) for alleged forged production date on biochemical drugs (resolved via mediation), and one against Shenzhen Huarun Sanjiu Medical Trade for alleged adulteration (no settlement reached).华润三九子公司新增两起消费者投诉：华润三九（南昌）药业被指伪造生化药品生产日期（已调解），深圳华润三九医药贸易被指掺假（未达成调解）。
2025-01-25A consumer complaint against China Resources Sanjiu was filed on the 12315 platform regarding quality issues of chemical APIs purchased via Pinduoduo's 999 official flagship store; mediation failed on January 24.华润三九新增1件消费者投诉，涉及在拼多多999官方旗舰店购买的化学原料药质量问题，调解未达成协议。
2025-06-18A consumer complaint was filed with the 12315 platform alleging quality issues (adulteration, counterfeit, substandard) in Chinese patent medicine purchased via online channel Ali Health; no settlement was reached.全国12315平台新增一起投诉，消费者反映通过阿里健康网购的中成药存在掺杂掺假、以假充真、以次充好问题，未达成调解协议。
2026-01-13Consumer complaint on product quality (Chinese and Western patent medicines) filed with 12315; resolved via mediation.消费者就中西成药质量问题向12315投诉，经调解达成协议。
ESG & sustainability recognitionESG与可持续发展认可
18 · 2024-06-19 → 2026-07-17
▾
Awards and ratings for ESG performance, CSR reporting, and sustainable development, including MSCI upgrade and various benchmark listings.在ESG表现、CSR报告和可持续发展方面获得奖项和评级，包括MSCI上调评级及各类榜单。
2024-06-19China Resources Sanjiu was rated 'Benchmark' (highest rating) for the second consecutive year in the 2023 special assessment of 'Ke Gai Demonstration Enterprises' by the SASAC, ranking in the top 10% among 349 enterprises and being the only pharmaceutical firm to receive this rating.华润三九在国资委2023年度“科改示范企业”专项考核中连续第二年获评最高评级“标杆”，在349户企业中排名前10%，是唯一获评的医药类企业。
2024-06-25China Resources Sanjiy's OTC business unit was named 'Benchmark Enterprise' in China Resources Group's 2023 list of world-class enterprise creation benchmarks.华润三九OTC事业部获评华润集团2023年度创建世界一流企业“标杆企业”。
2024-07-03China Resources Sanjiu's sustainable development experience was selected as a typical case in the 'China Enterprise Sustainable Development Report Guide (CASS-ESG 6.0) General Framework', and the company participated as a co-editor.华润三九可持续发展经验作为典型案例入选《中国企业可持续发展报告指南（CASS-ESG 6.0）之一般框架》，公司为参编单位之一。
2024-07-25China Resources Sanjiu won the 'ESG New Benchmark Enterprise Award' at the 2024 ESG Investment Value TOP100 List jointly issued by Securities Star and Huazheng Index.华润三九在证券之星联合华证指数发布的2024年ESG投资价值TOP100榜单中获颁“ESG新标杆企业奖”。
2024-07-26China Resources Sanjiu ranked first in the pharmaceutical corporate social responsibility survey list published by Southern Weekly's '2023 China Corporate Social Responsibility Survey List'.华润三九在《南方周末》发布的“2023年中国企业社会责任调研榜单”中位列医药企业社会责任调研榜第一。
2024-08-21CR Sanjiu's 2023 Sustainable Development and ESG Report received the GoldenBee 'Excellent (A+)' rating for corporate social responsibility reporting.华润三九《2023年可持续发展暨ESG报告》获金蜜蜂企业社会责任报告“卓越（A+）”评级。
2024-11-20China Resources Sanjiu was recognized as an 'ESG Governance Pioneer' at the 2024 'Responsibility Whale Award' and its sustainability practices were included in the CASS-ESG 6.0 industry guidelines as a case study.华润三九获评2024年“责任鲸牛奖”——ESG治理先锋，其可持续发展经验作为典型案例入选《中国企业可持续发展报告指南（CASS-ESG 6.0）》分行业指南。
2025-01-09China Resources Sanjiu held a kick-off meeting for the compilation of its 2024 Sustainable Development and ESG Report, with senior management emphasizing enhanced disclosure and integration of ESG into daily operations.华润三九召开2024年可持续发展暨ESG报告编撰启动会，高管强调加强信息披露并将ESG融入日常经营。
2025-05-24SASAC selected 'China Resources Sanjiu's Full Efforts to Promote the Construction of the TCM Industry Chain and Continuously Enhance Core Functions' as an excellent case in the 'Benchmarking World-Class Enterprises Value Creation Action'.国务院国资委将《华润三九全力推进中药产业链建设，持续增强核心功能》入选“国有企业对标世界一流企业价值创造行动”优秀案例。
2025-07-30Won 'ESG Benchmark Enterprise Award' and 'ESG Investment Value Award' at Securities Star's 3rd ESG New Benchmark Enterprise Selection; renewable energy usage ratio increased to 6.33%.在证券之星第三届ESG新标杆企业评选中荣获“ESG新标杆企业奖”及“ESG投资价值榜”；可再生能源使用比例提升至6.33%。
2025-08-04MSCI upgraded China Resources Sanjiu's ESG rating by two notches from BB to A.MSCI将华润三九的ESG评级由BB级上调两级至A级。
2025-11-25China Resources Sanjiu and its subsidiary Kunming Pharma won first and second prizes respectively in the 2025 Enterprise ESG Excellent Achievement Paper (Case) awards, organized by SASAC-affiliated journals.华润三九及昆药集团分别荣获‘2025年企业ESG优秀成果论文（案例）’一等奖及二等奖，该活动由国务院国资委主管的期刊组织。
2025-11-26China Resources Sanjiu ranked 4th in the 'China Enterprise Supply Chain ESG Top 100 Index' and was selected as an excellent case in the 'China Enterprise Supply Chain ESG Blue Book (2025)'.华润三九获评‘中国企业供应链ESG百强指数’第四名，并入选《中国企业供应链ESG蓝皮书（2025）》优秀案例。
2026-01-28Participated in the 'China Enterprise Supply Chain ESG Blue Book (2025)' research project (single-source direct procurement).参与《中国企业供应链ESG蓝皮书(2025)》课题项目，完成单源直接采购。
2026-02-26China Resources Sanjiu issued a procurement announcement for 'Near-Zero Carbon Park (TCM Manufacturing) Technical Standard Compilation and Implementation Services', with bid submission deadline March 8, 2026.华润三九发布'近零碳园区（中医药制造产业）技术标准编制与实施服务'采购公告，响应文件提交截止日期为2026年3月8日。
2026-04-242025 Sustainable Development/ESG Report received 'Five-Star Plus' highest rating for 3 consecutive years and a Silver Medal.《2025年可持续发展暨ESG报告》连续3年获“五星佳”最高评价，并获白银级勋章。
2026-06-23Received A-level ESG rating from CSI Index (China Securities Index), ranking 2nd among 12 A-share Chinese medicine companies.获得中证指数ESG评级A级，在A股中药Ⅲ行业12家公司中排名第2。
2026-07-17Won 'ESG New Benchmark Enterprise Award' and included in '2026 ESG Investment Value TOP100' list.荣获“ESG新标杆企业奖”，并入选“2026 ESG投资价值TOP100榜单”。
Chenzhou Huarun Gas energy supply郴州华润燃气能源供应
2 · 2024-06-21 → 2025-12-30
▾
Renewal of comprehensive energy supply agreements with Chenzhou Huarun Gas for the Chenzhou plant.与郴州华润燃气续签郴州工厂的综合能源供应协议。
2024-06-21China Resources Sanjiu's subsidiary Chenzhou Sanjiu renewed a comprehensive energy supply agreement with Chenzhou Huarun Gas, valid until Dec 31, 2025, with total transaction value not exceeding RMB 90 million (RMB 25 million for H2 2024, RMB 65 million for 2025).华润三九子公司郴州三九与郴州华润燃气续签综合能源供能协议，有效期至2025年12月31日，累计交易金额不超过9000万元（2024年下半年2500万元，2025年6500万元）。
2025-12-30Subsidiary Chenzhou Sanjiu renewed a comprehensive energy supply agreement with Chenzhou China Resources Gas for 2026-2028, with total consideration not exceeding RMB 99 million (RMB 30M/33M/36M per year).全资子公司郴州三九与郴州华润燃气续签综合能源供能协议，有效期2026-2028年，累计交易金额不超过9,900万元（每年3,000/3,300/3,600万元）。
Lianyungang intelligent packaging plant连云港智能包装工厂
1 · 2024-07-11
▾
New investment in a fully-automated pharmaceutical packaging production base in Lianyungang, Jiangsu.在江苏连云港投资建设全自动医药包装生产基地。
2024-07-11China Resources Sanjiu signed an intelligent pharmaceutical packaging project in Haizhou District, Lianyungang, Jiangsu, with a total planned investment of 1.1 billion yuan, covering 100 mu, expected annual output value of about 1.2 billion yuan, and tax revenue of 64 million yuan. The project will build 14 fully automatic inner and outer packaging production lines.华润三九在江苏连云港海州区签约智能医药包装项目，计划总投资额11亿元，占地100亩，预计年产值约12亿元，创造税收6400万元，将建设全自动内外包装生产线14条。
Market guidance & investor relations市场指引与投资者关系
3 · 2024-07-23 → 2025-04-15
▾
Earnings guidance, performance briefings, and investor Q&A sessions.业绩指引、业绩说明会及投资者问答活动。
2024-07-23China Resources Sanjiu stated in an institutional survey that its gross margin is expected to stabilize and have room for improvement in the long term, influenced by business structure, product seasonality, and expense timing.华润三九在机构调研中表示长期来看毛利率水平有望保持稳定并存在提升空间，受业务结构、产品季节性及费用投放节奏影响。
2024-08-23CR Sanjiu announced that its 2024 semi-annual performance briefing will be held on September 2, 2024, via online text interaction, with Chairman Qiu Huawei and other executives attending.华润三九公告2024年半年度业绩说明会将于2024年9月2日以网络文字互动形式举行，董事长邱华伟等高管出席。
2025-04-15China Resources Sanjiu guided that 2025 revenue is expected to achieve double-digit growth, with net profit matching revenue growth; it also noted that the government has issued a special action plan to promote health consumption.华润三九预计2025年营业收入将实现双位数增长，净利润将匹配营收增长水平；并提及相关部门已出台促进健康消费专项行动方案。
Raw material & supply chain strategy原料与供应链战略
10 · 2024-07-24 → 2026-08-20
▾
Strategy for securing raw materials through centralized procurement, origin cooperation, and GAP production, including the wild chrysanthemum project.通过集中采购、产地合作和GAP生产保障原料的战略，包括野菊花项目。
2024-07-24China Resources Sanjiu responded that the price of Chinese medicinal materials has risen to a certain extent this year, but the impact on overall cost is relatively small due to the wide variety of herbs used.华润三九回应中药材价格今年有一定幅度上涨，但因使用品种众多，对总体成本影响幅度相对较小。
2025-04-03China Resources Sanjiu stated that fluctuations in Sanqi (Panax notoginseng) prices have little impact on its core products, and the company has established centralized procurement and origin cooperation systems.华润三九表示，三七药材的涨跌对公司核心产品影响不大，公司在前端集中采购、产地合作等方面有较好的经验和体系。
2025-10-13China Resources Sanjiu disclosed its raw material strategy: centralized procurement, origin cooperation, GAP standardized production, and research on planting techniques for scarce herbs; its wild chrysanthemum project for 999 Ganmaoling won the 2023 National Science and Technology Progress Second Prize.华润三九披露原料策略：集中采购、产地合作、推广GAP标准化生产，并对稀缺药材加大种植技术研究；其999感冒灵原料野菊花项目荣获2023年度国家科学技术进步二等奖。
2026-01-26Guanlan base procured processed Chinese herbs (rice-fried Codonopsis, honey-fried licorice, earth-fried Angelica, Epimedium) for 2026.观澜基地完成2026年米炒党参、炙甘草、当归（土炒）、淫羊藿采购定价。
2026-01-26Guanlan base procured raw Chinese herbs (Codonopsis, licorice, Angelica) for 2026 from China Resources (Gansu) Chinese Medicine Technology Co., Ltd.观澜基地2026年党参、甘草、当归采购项目成交供应商为华润（甘肃）中药科技有限公司。
2026-03-06Company published single-source procurement result for 'Quality evaluation study of whole growth cycle of wild-to-cultivated Cibotium barometz'.公司发布'野生转家种金毛狗脊生长周期全过程质量评价研究'单源直接采购结果公告。
2026-05-20China Resources Sanjiu stated that its subsidiary in Youyang has sufficient capacity for artemisinin and derivatives; Kunming Pharma Group has built a full 'planting-extraction-synthesis-formulation' supply chain for artemisinin series with high raw material self-sufficiency.华润三九表示，其酉阳子公司青蒿素及衍生物产能充足；昆药集团内部已构建青蒿系列‘种植-提取-合成-制剂’全产业链协同，原料自给率高。
2026-05-20China Resources Sanjiu awarded a contract to Zhejiang Yingte Medical Herbs Co., Ltd. for trial production herbs for Huaganjian (a TCM formula), including Chenpi and Zhe Beimu.华润三九将化肝煎试生产药材采购项目授予浙江英特医药药材有限公司，采购物品包括陈皮和浙贝母。
2026-07-23Completed procurement for internal collaborative supply of some Chinese medicinal materials and decoction pieces for Guanlan base (Jul-Dec 2026).完成观澜基地2026年7-12月部分中药材、中药饮片内部协同供应采购定价项目。
2026-08-20Procurement result: Jiangxi Yipusheng Pharmaceutical selected as supplier for Guanlan base and China Resources Shunfeng joint procurement of glyceryl mono/distearate (Aug-Dec 2026).采购结果公告：江西益普生药业有限公司成为华润三九观澜基地、华润顺峰2026年8-12月单双硬脂酸甘油酯联合采购项目成交供应商。
China Development Bank financing deal国家开发银行融资合作
1 · 2024-07-29
▾
Strategic cooperation with China Development Bank Shenzhen Branch for a RMB 10 billion financing quota over five years.与国家开发银行深圳分行战略合作，五年内获得100亿元融资额度。
2024-07-29China Resources Sanjiu signed a strategic cooperation agreement with China Development Bank Shenzhen Branch, with an intended cooperation quota of 10 billion yuan in various financial products over a 5-year period to broaden financing channels and improve financing efficiency.华润三九与国家开发银行深圳市分行签署战略合作协议，意向合作额度100亿元人民币，有效期5年，以拓宽融资渠道、提高融资效率。
Tasly Pharmaceutical acquisition天士力收购
32 · 2024-08-04 → 2026-08-10
▾
CR Sanjiu's landmark cash acquisition of a 28% controlling stake in Tasly, from announcement through regulatory approvals and consolidation, creating a major TCM innovation platform.华润三九以现金收购天士力28%控股股权，从宣布、监管批准到并表，打造中药创新大平台。
2024-08-04China Resources Sanjiu (CR Sanjiu) announced a cash acquisition of 28% stake in Tasly Pharmaceutical (600535.SH) from Tasly Group and its concert parties for RMB 6.212 billion (RMB 14.85 per share), making CR Sanjiu the controlling shareholder and China Resources the ultimate controller.华润三九宣布以现金62.12亿元（每股14.85元）收购天士力集团及其一致行动人持有的天士力（600535.SH）28%股份，成为控股股东，实际控制人变更为中国华润。
2024-08-04Tasly Group also agreed to transfer an additional 5% of Tasly shares to China Reform Investment (Guoxin Investment) at RMB 14.85 per share, for a total consideration of approximately RMB 1.109 billion.天士力集团还同意以每股14.85元向国新投资转让天士力5%的股份，总对价约11.09亿元。
2024-08-04CR Sanjiu and its controlling shareholder China Resources Pharmaceutical Group issued a commitment letter to resolve horizontal competition with Tasly within five years after the transaction, covering retail pharmacy chains and eszopiclone products.华润三九及其控股股东华润医药控股出具承诺函，在交易完成后五年内解决与天士力在医药零售连锁和右佐匹克隆片等业务上的同业竞争问题。
2024-08-04CR Sanjiu's board of directors approved the major asset acquisition proposal for Tasly at its 15th board meeting held on August 3, 2024.华润三九董事会于2024年8月3日召开第十五次董事会会议，审议通过了关于天士力重大资产购买预案的议案。
2024-08-04CR Sanjiu disclosed that the acquisition of Tasly will be paid in three tranches: 35% within 10 working days after the agreement takes effect, with sufficient自有资金 to cover the payment.华润三九披露收购天士力将分三期付款，协议生效后10个工作日内支付35%首期股份转让款，公司自有资金充裕。
2024-08-05CR Sanjiu held an investor relations meeting attended by Chairman Qiu Huawei, VP Zhou Hui, and CFO Liang Zheng, discussing the Tasly acquisition and strategic synergy.华润三九召开投资者关系活动，董事长邱华伟、副总裁周辉、财务总监梁征出席，讨论收购天士力及战略协同。
2024-08-05CR Sanjiu stated that Tasly's management team will remain stable post-acquisition, with the principle of 'three stabilities' (team, customer, business) guiding integration.华润三九表示收购后天士力管理团队将保持稳定，以“三个稳定”（团队、客户、业务）为原则推进整合。
2024-08-31CR Sanjiu disclosed progress on the Tasly acquisition: due diligence, audit, and valuation are ongoing; the transaction still requires approvals from the board, shareholders, and state-owned assets supervision authorities.华润三九披露收购天士力进展：尽职调查、审计、评估等工作正在进行中，交易尚需董事会、股东大会及国资监管部门等审批。
2024-09-01China Resources Sanjiu signed a strategic cooperation agreement with Tasly, covering innovative Chinese medicine development, digital-intelligent herbal big model, and dropping pill technology and equipment development.华润三九与天士力签订战略合作协议，涵盖中药创新发展、数智本草大模型及滴丸技术与装备开发。
2024-09-24China Resources Sanjiu stated in an analyst meeting that the acquisition of Tasly will help it exceed its '14th Five-Year Plan' revenue doubling target, with the transaction expected to close in Q1 2025.华润三九在分析师会议上表示，收购天士力将助其超额完成'十四五'营收翻番目标，交易预计2025年一季度完成。
2024-09-29China Resources Sanjiu updated that the major asset restructuring to acquire 28% of Tasly (418 million shares) for cash is progressing; due diligence, audit, and valuation are ongoing, pending board and shareholder approvals.华润三九更新重大资产重组进展，拟现金收购天士力28%股份（4.18亿股），尽职调查、审计和评估进行中，尚需董事会和股东大会批准。
2024-10-25Announced a major asset restructuring plan to acquire 28% of Tasly Pharmaceutical's shares (418 million shares) for RMB 6.212 billion in cash; Tasly to become a controlled subsidiary.发布重大资产重组预案，拟以现金62.12亿元收购天士力28%股份（4.18亿股），交易完成后天士力将成为控股子公司。
2024-11-05China Resources Sanjiu announced a proposed acquisition of 28% stake in Tasly Pharmaceutical Group (600535.SH) for RMB 6.212 billion in cash, covering 418 million shares; the deal is expected to close by Q1 2025, aiming to strengthen TCM innovation capabilities.华润三九宣布拟以现金62.12亿元收购天士力医药集团28%股份（4.18亿股），预计2025年一季度完成交易，旨在补齐中药创新领域短板。
2024-11-28China Resources Sanjiu disclosed progress on the major asset restructuring to acquire 28% of Tasly; due diligence and valuation are ongoing, and the deal still requires board, shareholder, and regulatory approvals.华润三九披露重大资产重组进展：收购天士力28%股份的尽职调查、审计评估等工作正在进行中，尚需董事会、股东大会及监管机构批准。
2024-12-30Advancing acquisition of 28% equity (418,306,002 shares) in Tasly (天士力) via cash; will become controlling shareholder; due diligence and valuation ongoing.推进以现金收购天士力28%股份（418,306,002股）事项，交易完成后将成为控股股东；尽职调查、审计、评估等工作正在进行中。
2025-01-07China Resources Sanjiu confirmed that the major asset restructuring with Tasly (天士力) is ongoing; due diligence, audit, and valuation work are in progress, pending board and shareholder approvals.华润三九确认与天士力的重大资产重组正在进行中，尽职调查、审计和评估等工作推进中，尚需董事会和股东大会批准。
2025-02-04China Resources Sanjiu received the anti-monopoly review non-prohibition decision from the State Administration for Market Regulation for its acquisition of Tasly Pharmaceutical Group, allowing the concentration to proceed.华润三九收到国家市场监督管理总局关于收购天士力医药集团股权案的经营者集中反垄断审查不予禁止决定书，可以实施集中。
2025-02-06China Resources Sanjiu received approval from the State-owned Assets Supervision and Administration Commission (SASAC) for its acquisition of 418,306,002 shares (28% of total equity) in Tasly Pharmaceutical Group.华润三九收到国务院国资委批复，同意其协议受让天士力医药集团418,306,002股股份（占总股本28%）。
2025-02-17China Resources Sanjiu stated in an investor relations activity that the acquisition of Tasly is expected to close in Q1 2025, and that it will continue to seek high-quality integration opportunities in CHC and innovative drugs.华润三九在投资者关系活动中表示，收购天士力预计在2025年一季度完成交易，并继续关注CHC和创新药领域的优质整合机会。
2025-02-28China Resources Sanjiu announced it will acquire 418,306,002 shares (28%) of Tasly via cash payment, becoming the controlling shareholder; Tasly Group will also transfer 5% to China Reform Investment. The transaction requires shareholder meeting approval on March 21, 2025.华润三九公告拟以现金收购天士力418,306,002股（28%），成为控股股东；天士力集团另向国新投资转让5%股份。交易需3月21日股东大会审议。
2025-03-01China Resources Sanjiu announced a plan to acquire 28% of Tasly Pharmaceutical Group (600535.SH) shares for cash, with the deal valued at approximately 6.212 billion yuan, pending shareholder approval.华润三九公告拟以现金收购天士力医药集团28%股份，交易对价约62.12亿元，尚需股东大会审议。
2025-03-18China Resources Sanjiu released a revised major asset purchase report for the Tasly acquisition, responding to a Shenzhen Stock Exchange inquiry letter and updating 2024 financial data.华润三九发布天士力收购重大资产购买报告书修订稿，回应深交所问询函并更新2024年财务数据。
2025-03-27China Resources Sanjiu completed the acquisition of 28% of Tasly Pharmaceutical (418,306,002 shares) for cash; the share transfer was registered, making Tasly a subsidiary with China Resources as the new controlling shareholder.华润三九完成收购天士力28%股份（418,306,002股），股份过户登记完成，天士力成为控股子公司，实际控制人变更为中国华润。
2025-04-08China Resources Sanjiu stated that subsidiary Tasly (600535) reported 2024 operating cash flow of 2.01 billion yuan, with ample cash flow for the past three years.华润三九表示，子公司天士力（600535）2024年经营性现金流量净额为20.1亿元，近三年均保持在充沛水平。
2025-04-08China Resources Sanjiu stated that the acquisition of Tasly will leverage synergies in TCM planting, innovative R&D, smart manufacturing, and channel marketing, accelerating the supplementation of innovative TCM pipelines.华润三九表示，收购天士力将发挥双方在中药材种植、创新研发、智能制造、渠道营销等领域的协同效应，加快补充创新中药管线。
2025-05-06China Resources Sanjiu completed the consolidation of Tasly (600535) into its balance sheet at the end of Q1 2025; the acquisition had no impact on Q1 revenue or profit.华润三九于2025年一季度末完成对天士力（600535）的合并报表，该收购对一季度营收和利润无影响。
2025-07-03Completed acquisition of 28% equity in Tasly (天士力) in 2025Q1, making Tasly a controlled subsidiary; synergy expected in R&D, smart manufacturing, and channel marketing.2025年第一季度完成收购天士力28%股权，天士力成为控股子公司；预计在研发、智能制造和渠道营销方面产生协同效应。
2025-08-15China Resources Sanjiu completed acquisition of 28% stake in Tasly Pharmaceutical, consolidating Tasly as a subsidiary. Goodwill increased by CNY 1.921 billion from the acquisition.华润三九完成收购天士力28%股份，天士力成为控股子公司，因收购新增商誉19.21亿元。
2026-03-202025 annual report confirms completion of acquisition of 28% stake in Tasly Pharmaceutical Group, making it a controlled subsidiary, expanding prescription drug business.2025年年报确认完成收购天士力医药集团28%股份，天士力成为控股子公司，扩大处方药业务。
2026-03-202025 annual report shows prescription drug revenue of 12.094 billion yuan, up 101.38% YoY, driven by Tasly integration.2025年年报显示处方药业务收入120.94亿元，同比增长101.38%，受天士力整合驱动。
2026-03-212025 annual report shows total assets of 58.805 billion yuan, up 46.96% from beginning of year, mainly due to Tasly acquisition.2025年年报显示总资产588.05亿元，较年初增长46.96%，主要因收购天士力。
2026-08-10Zhou Hui resigned as chairman of Tasly Pharma due to retirement/工作调整, remaining as director; Xi Kai (former deputy GM, internal veteran) appointed general manager. Zhou had resigned from all parent China Resources Sanjiu director/executive roles on 2026-07-14.周辉因退休/工作调整卸任天士力董事长（仍任董事），席凯（内部老臣、曾任副总经理）出任总经理；周辉已于7月14日辞去华润三九母公司全部董事及高管职务。
Procurement & supplier contracts采购与供应商合同
50 · 2024-08-18 → 2026-08-19
▾
A wide range of routine procurement activities for raw materials, packaging, equipment, IT services, and marketing campaigns.涵盖原材料、包装、设备、IT服务和营销活动等各类日常采购活动。
2024-08-18CR Sanjiu issued a centralized procurement tender for ethanol (Zaozhuang) for H2 2024, with an estimated demand of 250 tons.华润三九发布2024年下半年（枣庄）乙醇集采招标公告，预估需求量250吨。
2026-01-23Awarded integrated printing system O&M service contract to Fujifilm Industrial Development (Shanghai) Co., Ltd.文印一体化系统运维服务采购项目成交供应商为富士胶片实业发展（上海）有限公司。
2026-01-23Awarded IT infrastructure technical service contract (single-source direct procurement).基础架构技术服务项目完成单源直接采购并确定成交供应商。
2026-01-23Awarded access control and LED screen system O&M service contract to Shenzhen Zhixunjiake Technology Co., Ltd.门禁及LED大屏系统运维服务项目成交供应商为深圳市智讯佳科技有限公司。
2026-01-26Awarded sales order OMS and 2 other system O&M service contract to Shanghai Defan Intelligent Technology Co., Ltd.销售订单OMS等3个系统运维服务采购项目成交供应商为上海得帆智能科技有限公司。
2026-01-27Awarded 2026 annual aluminum foil procurement contract to Sichuan Huili Industrial Co., Ltd. and Changzhou Huajian Pharmaceutical Packaging Materials Co., Ltd.2026年度铝箔采购项目成交供应商为四川汇利实业有限公司和常州市华健药用包装材料有限公司。
2026-01-27Awarded 2026 annual lab consumables procurement contract (negotiation procurement).2026年度实验耗材采购项目完成谈判采购并确定成交供应商。
2026-01-27Awarded content service and ad production for 999 Zhike Pipa Syrup to Beijing Xinyi Interactive Digital Technology Co., Ltd.999止咳枇杷糖浆内容服务和广告片制作项目成交供应商为北京新意互动数字技术有限公司。
2026-01-28Awarded entrusted production of Terbinafine Hydrochloride Spray (2026, Nanchang) to China Resources Sanjiu (Nanchang) Pharmaceutical Co., Ltd.盐酸特比萘芬喷雾剂2026年南昌地区委托生产服务商为华润三九（南昌）药业有限公司。
2026-01-28Awarded BOPP pharmaceutical packaging film procurement for Guanlan base (negotiation procurement).观澜基地BOPP药用包装膜采购项目完成谈判采购并确定成交供应商。
2026-01-28Awarded entrusted production of Compound Dexamethasone Acetate Cream (2026, Shunfeng) to Guangdong China Resources Shunfeng Pharmaceutical Co., Ltd.复方醋酸地塞米松乳膏2026年华润顺峰地区委托生产服务商为广东华润顺峰药业有限公司。
2026-01-28Awarded entrusted production of Oseltamivir Phosphate Capsules, Glucosamine Sulfate Capsules, Mizolastine SR Tablets (2026, Zhongyi) to Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.磷酸奥司他韦胶囊、硫酸氨基葡萄糖胶囊、咪唑斯汀缓释片2026年众益地区委托生产服务商为浙江华润三九众益制药有限公司。
2026-01-28Awarded entrusted production of Arginine Ibuprofen Granules (2026, Tangshan) to China Resources Sanjiu (Tangshan) Pharmaceutical Co., Ltd.精氨酸布洛芬颗粒2026年唐山地区委托生产服务商为华润三九（唐山）药业有限公司。
2026-02-25China Resources Sanjiu completed procurement for 'IT Desktop Operation and Maintenance Outsourcing Service'.华润三九完成'IT桌面运维外包服务'采购。
2026-02-26China Resources Sanjiu issued a procurement announcement for standard reference substances for Guanlan Base, with bid submission deadline March 3, 2026.华润三九发布观澜基地标准对照品采购公告，响应文件提交截止日期为2026年3月3日。
2026-02-26China Resources Sanjiu completed procurement for '2026 Shenzhen Guanlan Park Non-production and Production Area Maintenance and Renovation Project'.华润三九完成'2026年度深圳观澜园区非生产、生产区域维修及改造工程'采购。
2026-05-11China Resources Sanjiu awarded a contract to China Inspection and Certification Group Shenzhen Co., Ltd. for energy review technical services at the Guanlan base.华润三九将观澜基地能源评审技术服务项目授予中国检验认证集团深圳有限公司。
2026-05-12China Resources Sanjiu awarded a contract to Shanghai Shutu Health Pharmaceutical Technology Co., Ltd. for research on key regional innovation platform layout and planning.华润三九将重点区域创新平台布局与策划研究项目授予上海数图健康医药科技有限公司。
2026-05-27China Resources Sanjiu awarded a contract to JD Logistics for logistics services at Anhui Jinchan.华润三九将安徽金蟾物流服务采购项目授予京东物流运输有限公司。
2026-05-27China Resources Sanjiu awarded a contract to Foshan Shunde Shunfeng Pharmaceutical Packaging Materials Co., Ltd. for aluminum tube supply from May 2026 to May 2027.华润三九将2026年5月至2027年5月铝管直接采购项目授予佛山市顺德区顺峰药品包装材料有限公司。
2026-05-29China Resources Sanjiu awarded a contract to Jiangsu Jinyi United Intelligent Manufacturing Co., Ltd. for moulds supporting new capsule specifications at the Guanlan base capsule packaging line.华润三九将观澜基地胶囊剂外包产线新增品规配套模具采购项目授予江苏仅一联合智造有限公司。
2026-05-29China Resources Sanjiu awarded a contract to Huizhou Jiuhui Pharmaceutical Co., Ltd. for entrusted processing supporting services in Huizhou.华润三九将惠州委托加工配套服务采购项目授予惠州市九惠制药股份有限公司。
2026-06-15Completed single-source direct procurement for SJWTKL pharmaceutical research project; supplier is Benxi National Chinese Medicine Engineering Technology Research Center Co., Ltd.SJWTKL药学研究项目单源直接采购完成，成交供应商为本溪国家中成药工程技术研究中心有限公司。
2026-06-15Completed single-source direct procurement for membrane separation technology research project (common technology).共性技术-膜分离技术研究项目单源直接采购完成。
2026-06-24Launched procurement for development research of constipation-relieving functional probiotics; intended partner is China Agricultural University.发布缓解便秘功能益生菌的开发研究采购公告，拟邀请单位为中国农业大学。
2026-06-26Completed procurement for stability study of eye drop project (滴眼液项目稳定性研究); supplier is Tianjin Hancang Pharmaceutical Biotechnology Co., Ltd.滴眼液项目稳定性研究采购完成，成交供应商为天津市汉康医药生物技术有限公司。
2026-07-01Announced procurement for comprehensive market research services for 2026-2027, requiring drug-related consumer usage and attitude studies.发布2026-2027年综合型市场调研服务采购公告，要求药品相关消费者使用与态度研究业绩。
2026-07-02Completed procurement for automation upgrade of capsule packaging line at Guanlan base, supplier Shenzhen Yuantai Purification Technology.完成观澜基地胶囊剂外包产线自动化升级项目配套工程采购，成交供应商为深圳市元泰净化科技有限公司。
2026-07-02Completed procurement for development research of constipation-relieving functional probiotics.完成缓解便秘功能益生菌的开发研究采购。
2026-07-02Selected suppliers for 2026 999 creative marketing project: Shangqi Advertising, Shanghai Tubie Information Technology, and Microcosm (Beijing) Creative Culture.确定2026年999创意营销项目三个标段的成交供应商：上麒广告、上海图呗信息科技、微观宇宙（北京）创意文化。
2026-07-02Completed procurement for Aonuo Phase II optimization project, supplier Shanghai Huantong Business Technology.完成澳诺二期优化项目采购，成交供应商为上海寰通商务科技有限公司。
2026-07-03Selected three suppliers for 999 series health science popularization project: Guangzhou Yishi, Tianlulu, Wuhan Yipu.确定999系列产品健康科普采购项目三家成交供应商：广州医视、天呐噜噜、武汉医普。
2026-07-07Announced procurement for TOC analyzers and portable water quality testers.发布TOC分析仪和便携式水质测试仪采购公告。
2026-07-07Completed procurement for 2026-2027 Tencent drama advertising placement, supplier Shunfeng Media Group.完成2026-2027年腾讯大剧投放项目采购，成交供应商为舜风传媒集团股份有限公司。
2026-07-17Completed procurement for 2026 sealing tester purchase.完成2026年密封性测试仪采购项目。
2026-07-17Completed procurement for 2026 nitrogen generator purchase.完成2026年氮气发生器采购项目。
2026-07-17Completed procurement for 2026 microscope purchase, supplier Guangzhou Zepu Technology.完成2026年显微镜采购项目，成交供应商为广州择谱科技有限公司。
2026-07-23Announced procurement for China Association of Traditional Chinese Medicine Intelligent Manufacturing Committee 2026 annual meeting project.发布中国中药协会中药智能制造专委会2026年会项目采购结果公示。
2026-07-27Announced procurement for 2026 formulation equipment validation services.发布研发2026年度制剂设备验证服务采购公告。
2026-07-27Completed procurement for Guanlan base 'Red Tree Plan' graduation study tour, supplier Guangzhou Lanling Enterprise Management Consulting.完成观澜基地红树计划结业游学项目采购，成交供应商为广州蓝令企业管理咨询有限公司。
2026-07-30Completed procurement for 2026 999 all-product outdoor creative marketing project, supplier Guangzhou Youle Creative Consulting.完成2026年999全产品户外创意营销项目采购，成交供应商为广州有了创意咨询有限公司。
2026-08-01Procurement result: Q3 2026 Sanjiu Weitai content marketing project (3 packages) completed evaluation, selecting suppliers for content marketing.采购结果公告：2026年Q3三九胃泰内容营销项目（三个标包）完成评审，确定成交供应商。
2026-08-01Procurement result: '2026 China Resources Sanjiu Aonuo Business School Peking University CEO class design & construction' project completed evaluation.采购结果公告：“博雅学海 论道强骨”2026华润三九澳诺商学院北大总裁班设计搭建采购项目完成评审。
2026-08-05Procurement result: China Federation of Industrial Economics selected as supplier for 'Central-local collaborative empowerment of TCM industry high-quality development blue book research and publication' project.采购结果公告：中国工业经济联合会成为“央地协同赋能中医药产业高质量发展蓝皮书研究与发布”项目供应商。
2026-08-08Procurement announcement: Yixue Sheng Capsule (blood-enriching) pharmacy real-world research technical service project published; response deadline 2026-08-18.采购公告：益血生胶囊药店真实世界调研技术服务项目发布，响应文件截止2026年8月18日。
2026-08-12Procurement announcement: Guanlan base environmental protection facility upgrade - waste gas treatment low-efficiency facility renovation project tender published.采购公告：观澜基地环保设施改造升级-废气治理低效设施改造项目招标发布。
2026-08-12Procurement announcement: 'China Resources Sanjiu 26-27 Xiaohongshu content marketing project' negotiation procurement published.采购公告：“华润三九26至27年小红书内容营销项目”谈判采购发布。
2026-08-13Procurement result: '2026 Sanjiu Weitai Bilibili Yu Qian video podcast cooperation project' completed evaluation (announced 2026-08-07), selecting content marketing partner for Bilibili podcast with comedian Yu Qian.采购结果公告：“2026年三九胃泰B站于谦视频播客合作项目”完成评审（8月7日发布），确定与于谦在B站开展视频播客内容营销合作。
2026-08-13Procurement result: Shenzhen No.1 Construction Engineering selected as supplier for science park fire protection facility maintenance project.采购结果公告：深圳市壹号建设工程有限公司成为科创园区消防设施系统维修保养项目成交供应商。
2026-08-19Procurement result: Anhui China Resources Jinchan Pharmaceutical selected as supplier for R&D materials entrusted management project.采购结果公告：安徽华润金蟾药业有限公司成为研发物料委托管理采购项目成交供应商。
Tencent Cloud & AI (Sanjiu Health Butler)腾讯云与AI（三九健康管家）
2 · 2024-09-05 → 2026-07-23
▾
Strategic cooperation with Tencent Cloud to launch the 'Sanjiu Health Butler' AI assistant and adopt cloud computing and AI technologies.与腾讯云战略合作，推出'三九健康管家'AI助手，并采用云计算和AI技术。
2024-09-05China Resources Sanjiu signed a strategic cooperation agreement with Tencent Cloud; jointly launched the 'Sanjiu Health Butler' AI assistant based on Tencent's medical large model and cloud computing.华润三九与腾讯云签订战略合作协议；共同发布基于腾讯医疗大模型和云计算的'三舅健康管家'AI智能助手。
2026-07-23Completed procurement for unified technical base (container project phase II), supplier Tencent Cloud Computing (Beijing).完成统一技术底座（容器项目二期）采购，成交供应商为腾讯云计算（北京）有限责任公司。
Regulatory policy & VBP impact监管政策与集采影响
3 · 2024-09-09 → 2026-04-09
▾
Responses to and management of regulatory changes, including provincial VBP for TCM, national medical insurance negotiations, and label revisions.应对和管理监管变化，包括中药省级集采、国家医保谈判和说明书修订。
2024-09-09Anhui Provincial Medical Consortium issued a draft for centralized volume-based procurement of 35 Chinese patent medicines, including Ganmaoling granules/capsules (999 Ganmaoling), a core OTC product of China Resources Sanjiu.安徽省医药联合采购办公室发布35个中成药集中带量采购征求意见稿，包括感冒灵颗粒/胶囊（999感冒灵），为华润三九核心OTC产品。
2024-09-11China Resources Sanjiu responded that the Anhui procurement draft has limited impact on 999 Ganmaoling, as it is an OTC product not in the national medical insurance catalog, and will actively communicate during the comment period.华润三九回应称安徽集采征求意见稿对999感冒灵影响有限，因其为OTC产品且不在国家医保目录，将在征求意见期内积极沟通。
2026-04-09Confirmed no products have 'unknown' labels in contraindications/adverse reactions/precautions that would fail review under the 2026 TCM registration regulation transition.确认暂无因说明书【禁忌】【不良反应】【注意事项】标注为“尚不明确”而不予通过审核的产品，符合2026年中药注册管理专门规定过渡期要求。
Dyne Pharmaceutical distribution deal达因药业分销协议
1 · 2024-09-18
▾
Exclusive distribution agreement with Dyne Pharmaceutical for its Vitamin D Drops in China.与达因药业签署独家经销协议，负责其维生素D滴剂在中国市场的销售。
2024-09-18China Resources Sanjiu signed a strategic cooperation agreement with Dyne Pharmaceutical (Shandong) to become the exclusive distributor in China for Dyne's Vitamin D Drops (capsule type), covering marketing and full-channel sales.华润三九与山东达因药业签署战略合作协议，成为达因维生素D滴剂（胶囊型）在中国境内的独家代理商，负责市场推广和全渠道营销。
Awards & certifications奖项与认证
2 · 2024-10-21 → 2025-03-05
▾
Recognition for AI applications, high-tech enterprise status, and other official certifications.在AI应用、高新技术企业资格及其他官方认证方面获得的认可。
2024-10-21AI-empowered creative design for the pharmaceutical field received 'AI Industry Innovation Scenario Application Case' certification from MIIT Industrial Culture Development Center.“AI赋能医药领域创意设计”获得工信部工业文化发展中心“AI产业创新场景应用案例”认证。
2025-03-05China Resources Sanjiy received a High-Tech Enterprise Certificate (valid 2024-2026), entitling it to a 15% corporate income tax rate for three years.华润三九获得高新技术企业证书（有效期2024-2026年），可享受15%企业所得税优惠税率。
Digital & smart manufacturing transformation数字化与智能制造转型
21 · 2024-11-11 → 2026-08-20
▾
Company-wide digital transformation initiatives including the Deep Blue Smart Manufacturing Lab, FLUX WMS deployment, AI-driven marketing, and various IT system upgrades.公司级数字化转型，包括深蓝智能制造实验室、FLUX WMS部署、AI驱动营销及各类IT系统升级。
2024-11-11China Resources Sanjiu partnered with FLUX Technology to deploy FLUX WMS across over 40 subsidiaries for unified warehouse and logistics management, integrating with ERP systems for GMP/GSP compliance.华润三九与富勒科技合作，在其旗下40多家子公司部署FLUX WMS，实现仓储物流集团化统一管理，对接ERP系统并符合GMP/GSP规范。
2025-03-10China Resources Sanjiu disclosed that its Deep Blue (Smart Manufacturing) Lab uses 5G, blockchain, digital twins, cloud computing, and AI to upgrade traditional pharmaceutical manufacturing.华润三九披露其深蓝（智能制造）实验室运用5G、区块链、数字孪生、云计算、AI等技术升级传统药品制造体系。
2025-03-21China Resources Sanjiu announced it was selected as a national 'Smart Manufacturing Benchmark Enterprise' by the Ministry of Industry and Information Technology and received the 'Integration of Informatization and Industrialization Management System Certification'.华润三九入选工信部“智能制造标杆企业”，并获得“两化融合管理体系评定证书”。
2025-05-06China Resources Sanjiy was selected as a 'Smart Manufacturing Benchmark Enterprise' by MIIT, and obtained the 'Integration of Informatization and Industrialization Management System Certification'.华润三九入选工信部“智能制造标杆企业”，并获得“两化融合管理体系评定证书”。
2025-09-10China Resources Sanjiu disclosed that its Deep Blue (Smart Manufacturing) Lab is upgrading traditional pharmaceutical manufacturing with equipment technology to accelerate digital transformation and TCM modernization. In marketing, it launched the 'Sanjiu Health AI Agent' for consumer health information and uses large models to generate ad images, copy, and promotional videos.华润三九披露其深蓝（智能制造）实验室运用设备技术升级传统药品制造体系，加快数字化转型及中药现代化进程；营销领域发布三舅健康智能体，并通过大模型创作广告图片、文案和宣传视频。
2026-02-26China Resources Sanjiu completed procurement for 'Quality AI Assistant Project', with winning supplier being Beijing Shangzhi Hegui Technology Co., Ltd. (北京尚质合规科技有限公司).华润三九完成'质量AI助手项目'采购，成交供应商为北京尚质合规科技有限公司。
2026-06-18Completed procurement for Smart Operations Brain (智慧运营大脑) project via inquiry; pre-selected supplier announced.智慧运营大脑项目询比采购完成，预成交供应商公示。
2026-06-24Completed procurement for firewall domestic replacement project (防火墙国产化替换采购项目).防火墙国产化替换采购项目完成。
2026-06-29Completed single-source direct procurement for CRM 2026 requirements (CRM2026年需求采购).CRM2026年需求采购项目单源直接采购完成。
2026-07-01Launched procurement for BI platform and general application operations and maintenance services.启动BI平台及通用应用运维采购项目。
2026-07-02Completed procurement for industrial internet platform pilot - planting application construction.完成工业互联网平台试点-种植应用建设项目采购。
2026-07-02Completed procurement for smart operations brain project.完成智慧运营大脑项目采购。
2026-07-02Completed procurement for mini-program development for group anniversary event, supplier Hangzhou Youzan Technology.完成小程序开发-集团周年活动采购，成交供应商为杭州有赞科技有限公司。
2026-07-03Completed procurement for R&D Diebian platform upgrade, supplier Beijing Ruijie Intelligent Technology.完成研发蝶变平台升级项目采购，成交供应商为北京瑞杰智能科技有限公司。
2026-07-06Announced procurement for IT infrastructure technical services.发布IT基础架构技术服务采购公告。
2026-07-06Completed procurement for EHS smart management platform project.完成EHS智慧管理平台项目采购。
2026-07-12Completed procurement for industrial internet platform pilot - visual AI analysis capability construction, supplier Sitong Shuke (Nanjing).完成工业互联网平台试点-视觉AI分析能力建设项目采购，成交供应商为思通数科（南京）信息技术有限公司。
2026-07-23Completed procurement for Alibaba regulatory code platform.完成阿里监管码平台采购项目。
2026-07-24Completed procurement for industrial internet platform pilot - traceability application construction, supplier Beijing Jiahua Huicheng Technology.完成工业互联网平台试点-溯源应用建设项目采购，成交供应商为北京嘉华汇诚科技股份有限公司。
2026-08-13Procurement announcement: 'TCM quality digitalization Special 22 (production operation cockpit phase II, SRM, multi-dimensional production quality data analysis)' dedicated equipment procurement result announced (2026-08-12), supporting digital quality management upgrades.采购结果公告：“中药质量数字化22号专项（生产运营驾驶舱二期、SRM、多维度生产质量数据分析等数据类项目）专用设备采购”完成评审（8月12日发布），为中药生产数字化和质量管控提供设备支持。
2026-08-20Registered new software copyright 'China Resources Sanjiu Intelligent Inspection Robot Management Platform V1.0'; total 4 software copyrights registered YTD, up 300% yoy; 2025 R&D spend RMB 1.268bn (+58.16% yoy).新注册《华润三九智能巡检机器人管理平台V1.0》软件著作权；今年以来共新注册软件著作权4个，同比增加300%；2025年研发投入12.68亿元，同比增58.16%。
Executive & governance高管与治理
12 · 2024-12-19 → 2026-06-26
▾
Board decisions on audits, related-party transactions, internal rules, capital changes, and shareholder meetings.董事会关于审计、关联交易、内部制度、资本变动及股东大会的决策。
2024-12-19Registered capital increased from approximately 988 million yuan to approximately 1.284 billion yuan; multiple key personnel changed.注册资本由约9.88亿人民币增至约12.84亿人民币；多位主要人员发生变更。
2024-12-25Announced 2025 first extraordinary general meeting on Jan 17, 2025 to vote on 'Proposal on Estimated Amount of 2025 Daily Related Party Transactions'.公告将于2025年1月17日召开2025年第一次临时股东大会，审议《关于2025年度日常关联交易预计金额的议案》。
2025-06-17Board approved a product co-development R&D proposal and revised the investment management system.董事会通过了产品合作研发的议案，并修订了投资管理制度。
2025-08-15China Resources Sanjiu's board approved the reappointment of KPMG Huazhen LLP as the 2025 auditor; the proposal requires shareholder approval.华润三九董事会审议通过续聘毕马威华振会计师事务所为2025年度审计机构，该议案尚需提交股东会审议。
2025-12-09Board of Directors approved the 2026 annual related-party transaction estimate, with total transactions not exceeding RMB 4,944.2753 million (sales to related parties ≤ RMB 4,462.9211 million, purchases ≤ RMB 481.3542 million).董事会审议通过2026年度日常关联交易预计金额议案，总额不超过494,427.53万元（向关联方销售不超过446,292.11万元，采购不超过48,135.42万元）。
2025-12-09Board of Directors approved the revision of the Company's Articles of Association, abolishing the Board of Supervisors and transferring its functions to the Audit Committee, and adjusting total shares to 1,664,217,858 and registered capital to RMB 1,664,217,858 after share buyback cancellation.董事会审议通过修订《公司章程》，取消监事会并由审计委员会行使监事会职权，回购注销限制性股票后总股本变更为1,664,217,858股，注册资本变更为1,664,217,858元。
2025-12-09Board of Directors approved the 2025 audit fee of RMB 3.45 million and decided to revise the enterprise annuity plan.董事会确定2025年度审计费用为345万元，并决定修订企业年金方案。
2025-12-09Board of Directors approved the revision of multiple internal governance rules including the Independent Director Working System, Related-Party Transaction Management Measures, and Information Disclosure Management System, to be submitted to the shareholders' meeting.董事会审议通过修订《独立董事工作制度》、《关联交易管理办法》、《信息披露事务管理制度》等多项内部治理制度，将提交股东会审议。
2025-12-09Board of Directors approved the establishment of the 'Information Disclosure Suspension and Exemption Business Management System'.董事会审议通过制定《信息披露暂缓与豁免业务管理制度》。
2026-01-05Subsidiary energy procurement related-party transaction announced.子公司采购能源关联交易公告发布。
2026-03-21Board approved related-party financial cooperation with Guangdong China Resources Bank, with cumulative bill discounting not exceeding 1 billion yuan per 12 months.董事会批准与广东华润银行开展金融业务合作，每12个月累计票据贴现金额不超过10亿元。
2026-06-262026 first extraordinary general meeting approved three proposals; attended by 773 shareholders representing 64.97% of voting shares.2026年第一次临时股东会审议通过三项议案，出席股东代表股份占公司有表决权股份总数的64.97%。
Overseas & Hong Kong expansion海外与香港拓展
3 · 2024-12-25 → 2026-08-13
▾
Early-stage exploration of overseas markets and Hong Kong TCM innovation activities, including the Shenzhen Huarun Tang retail expansion.初步探索海外市场及香港中药创新活动，包括深圳华润堂的零售扩张。
2024-12-25As of Nov 2024, Shenzhen Huarun Tang (深圳华润堂) operates 18 standalone stores in Shenzhen and Guangzhou, plus multiple joint stores in Shenzhen, Guangzhou, Beijing, Shanghai.截至2024年11月，深圳华润堂在深圳、广州共有18家独立门店，在深圳、广州、北京、上海等地设有多家联营门店。
2025-04-24China Resources Sanjiu stated that its overseas business accounts for a small proportion of total revenue, and it will follow the national strategy to actively explore overseas promotion of its products.华润三九表示，公司海外业务在总体业务中占比较小，将跟随国家战略，积极探索公司产品向海外推广。
2026-08-13Procurement announcement: Hong Kong TCM innovation R&D international academic symposium conference service project published.采购公告：香港中医药创新研发国际学术研讨会会议服务项目发布。
JD Health strategic cooperation京东健康战略合作
3 · 2024-12-31 → 2026-04-28
▾
Strategic partnership with JD Health for omnichannel retail, digital marketing, and CSR, including the exclusive online launch of Yiqi Qingfei Granules.与京东健康达成战略合作，涵盖全渠道零售、数字营销和CSR，包括益气清肺颗粒的独家线上首发。
2024-12-31Signed strategic cooperation agreement with JD Health (京东健康) to deepen omnichannel retail, digital marketing, and CSR over the next year.与京东健康签署战略合作协议，未来一年在医药零售全渠道、医药数字化营销、企业社会责任等领域全面深化合作。
2025-01-02China Resources Sanjiu signed a strategic cooperation agreement with JD Health covering omnichannel pharmaceutical retail, digital marketing, and corporate social responsibility for the coming year.华润三九与京东健康签署战略合作协议，未来一年将在医药零售全渠道、数字化营销和企业社会责任等领域深化合作。
2026-04-28Launched the 'Grassroots Health Protection Plan' with JD Health to promote high-quality TCM services to primary care, leveraging AI tools and JD Logistics.与京东健康共同发起“基层健康守护计划”，依托AI工具和京东物流，推动优质中医药服务向基层下沉。
Yiqi Qingfei Granules (Zhang Boli collaboration)益气清肺颗粒（张伯礼合作）
10 · 2025-01-10 → 2026-06-15
▾
Development, approval, launch, and market access of the first TCM 3.2-class new drug 999 Yiqi Qingfei Granules, co-developed with Academician Zhang Boli for respiratory infection recovery.与张伯礼院士合作研发的999益气清肺颗粒，作为首个3.2类中药新药获批、上市并进入医保。
2025-01-10China Resources Sanjiu's Yiqi Qingfei Granules (益气清肺颗粒), a Category 3.2 new traditional Chinese medicine drug co-developed with Academician Zhang Boli, received NMPA approval for post-epidemic symptoms such as fatigue and dry cough.华润三九与中国工程院院士张伯礼共同研发的益气清肺颗粒（中药3.2类新药）获国家药监局批准，用于疫后倦怠乏力、干咳等症状。
2025-03-28China Resources Sanjiu, in collaboration with academician Zhang Boli, developed the first TCM innovative drug '999 Yiqi Qingfei Granules' officially approved by the NMPA for comprehensive symptoms during respiratory infection recovery.华润三九携手张伯礼院士研发的“999益气清肺颗粒”获国家药监局正式批准，为首个针对呼吸道感染康复期综合症状的中药创新药。
2025-04-02China Resources Sanjiu released its first TCM 3.2-class new drug, 999 Yiqi Qingfei Granules, developed with academician Zhang Boli and team, the first NMPA-approved TCM innovative drug specifically for comprehensive symptoms during respiratory infection recovery.华润三九发布首个中药3.2类新药——999益气清肺颗粒，由公司携手中国工程院院士张伯礼及团队共同研发，是首个获国家药监局正式批准、专门针对呼吸道感染康复期综合症状治疗的中药创新药。
2025-04-30China Resources Sanjiu's first TCM 3.2-class new drug, 999 Yiqi Qingfei Granules, was approved and officially released during Q1 2025, marking the company's full-scenario respiratory category layout.华润三九首个中药3.2类新药999益气清肺颗粒于报告期内获批并正式发布，标志着公司呼吸品类实现全场景渗透的生态化布局。
2025-07-03First Chinese medicine class 3.2 new drug 999 Yiqi Qingfei Granules approved and officially released in 2025Q1, marking full-scenario penetration of respiratory category.2025年第一季度，首个中药3.2类新药999益气清肺颗粒获批并正式发布，标志着呼吸品类实现全场景渗透。
2025-08-15China Resources Sanjiu's 2025 H1 R&D spending reached CNY 662 million, up 68.99% YoY. The company obtained 8 Drug Registration Certificates and launched its first Category 3.2 new TCM drug, 999 Yiqi Qingfei Granules.华润三九2025年上半年研发投入6.62亿元，同比大增68.99%；获得8个《药品注册证书》，首个中药3.2类新药999益气清肺颗粒获批上市。
2025-12-04China Resources Sanjiu and Academician Zhang Boli's team jointly developed 999 Yiqi Qingfei Granules, the first domestic respiratory infection recovery drug, launched online on JD Health.华润三九与中国工程院院士张伯礼团队共同研发的999益气清肺颗粒，国内首款呼吸道感染康复用药，在京东健康线上首发。
2025-12-08999 Yiqi Qingfei Granules were included in the National Medical Insurance Catalog (2025 version) for the first time via negotiation, effective from 2026-01-01 to 2027-12-31.999益气清肺颗粒通过谈判首次纳入《国家医保目录（2025年）》，协议有效期2026年1月1日至2027年12月31日。
2026-02-27China Resources Sanjiu's 999 'Yiqi Qingfei Granules' (益气清肺颗粒) has been included in the national medical insurance catalog and launched exclusively on JD Health.华润三九的999'益气清肺颗粒'已纳入国家医保目录，并在京东健康独家首发。
2026-06-15Product 999 Yiqi Qingfei Granules (益气清肺颗粒) has entered 200 medical institutions at various levels for academic promotion and online sales.999益气清肺颗粒已进入200家各级医疗机构，开展上市后学术推广和挂网销售。
ESG & green initiativesESG与绿色倡议
1 · 2025-01-14
▾
Community welfare campaigns and charitable activities, including winter donations and health stations.社区福利活动和慈善项目，包括冬季捐赠和爱心驿站。
2025-01-14China Resources Sanjiu partnered with Dingdang Kuaiyao to launch a 'Warmth on the Road' campaign, donating winter clothing and supplies to elderly communities and setting up爱心驿站 (love stations) at 20+ stores in Beijing.华润三九携手叮当快药发起“总有温暖在路上”暖心行动，向社区老人捐赠防寒物资，并在北京20余家门店设立爱心驿站。
IP & patents知识产权与专利
4 · 2025-03-10 → 2026-05-28
▾
Trademark filings, software copyrights, and clarifications on data integrity and IP ownership.商标申请、软件著作权登记，以及数据完整性和知识产权归属的澄清。
2025-03-10China Resources Sanjiu denied data integrity issues for its tenofovir alafenamide fumarate bioequivalence study, stating a published article had data pasting errors which have been corrected.华润三九否认富马酸丙酚替诺福韦片生物等效性研究数据真实性问题，称已发表文章存在数据粘贴错误并已勘误。
2025-03-14China Resources Sanjiu filed two new trademark applications, including 'Yingyang Lianmeng', bringing its total registered trademarks to 4,050.华润三九新提交“盈养联盟”等2件商标注册申请，累计持有注册商标4050件。
2025-08-06China Resources Sanjiu confirmed in an investor Q&A that it already holds the technology and IP rights for the QHB-196 project, a Class 1 small-molecule targeted anti-tumor new drug.华润三九在投资者互动平台确认，公司已持有QHB-196项目（1类小分子靶向抗肿瘤新药）的技术成果及知识产权。
2026-05-28China Resources Sanjiu registered a new software copyright for 'China Resources Sanjiu TCM GAP Management Traceability System V2.0'.华润三九新注册了《华润三九中药材GAP管理追溯系统V2.0》项目的软件著作权。
Asset divestitures & equity transfers资产剥离与股权转让
3 · 2025-05-15 → 2025-06-06
▾
Divestiture of non-core assets such as stakes in Hubei Jointown and Sanjiu (Anguo), and the internal transfer of Kunming Shenghuo.剥离非核心资产，如湖北九州通和安国三九的股权，以及内部转让昆明圣火。
2025-05-15China Resources Sanjiu publicly listed for transfer its 51% stake in Hubei Jointown Pharmaceutical Technology Co., Ltd. at a base price of 10.86 million yuan.华润三九公开挂牌转让所持湖北九州通医药科技有限公司51%股权，转让底价1086万元。
2025-05-16China Resources Sanjiu also listed for transfer its entire stake in Sanjiu (Anguo) Modern Chinese Medicine Development Co., Ltd., with cumulative base price of 12.4815 million yuan for both transfers.华润三九还挂牌转让所持三九（安国）现代中药开发有限公司全部股权，两笔转让累计底价1248.15万元。
2025-06-06China Resources Sanjiu is divesting its 49.8967% stake in Sanjiu (Anguo) Modern Chinese Medicine Development Co., Ltd., which had zero revenue for two consecutive years (2023-2024 net losses of -66.53万元 and -129.14万元), and its joint venture Hubei Jiuzhoutong Pharmaceutical Technology Co., Ltd. turned from profit to loss in Q1.华润三九正在折价抛售连续两年零收入的三九(安国)现代中药开发有限公司49.8967%股权（2023-2024年净利润分别为-66.53万元、-129.14万元），合资的湖北九州通医药科技有限公司一季度业绩由盈转亏。
Cell & gene therapy (CGT) ventures细胞与基因治疗（CGT）布局
4 · 2025-06-24 → 2026-05-20
▾
Entry into cell and gene therapy through a co-development deal for HiCM-188 (iPSC-derived cardiomyocytes) and a joint lab with Shenzhen Third People's Hospital.通过与HiCM-188（iPSC衍生心肌细胞）共同开发及与深圳市第三人民医院共建联合实验室，进入细胞与基因治疗领域。
2025-06-24China Resources Sanjiu signed a joint development agreement with Nanjing Aierpu Regenerative Medicine for HiCM-188 (iPSC-derived cardiomyocytes) in mainland China; HiCM-188 is the first 'off-the-shelf' cell innovative drug to receive IND registration in both China and the US, targeting severe heart failure.华润三九与南京艾尔普再生医学签署HiCM-188（iPSC来源心肌细胞）在中国大陆地区的联合开发协议；HiCM-188是全球首款在中美同时获得IND注册的“现货型”细胞创新药，瞄准重度心衰。
2025-07-07Partnered with Ailpu Regenerative Medicine (艾尔普再生医学) to co-develop HiCM-188, China's first self-developed iPSC-derived cardiomyocyte drug for heart failure, an 'off-the-shelf' cell therapy with IND approvals in both China and the US.与艾尔普再生医学合作，共同开发HiCM-188——中国首款自研iPSC来源心肌细胞药物，用于心衰治疗，为“现货型”细胞创新药，已在中美同时获得IND注册。
2026-04-27Signed strategic cooperation agreement and jointly established a Cell and Gene Therapy (CGT) joint laboratory with Shenzhen Third People's Hospital.与深圳市第三人民医院签署战略合作协议，并揭牌共建细胞与基因治疗（CGT）联合实验室。
2026-05-20China Resources Sanjiu disclosed in investor interaction that it is actively deploying cell and gene therapy (CGT), with multiple pipelines in research, and has entered a joint R&D cooperation on HiCM-188, a first-in-class iPSC-based heart failure regenerative therapy approved for clinical trials in both China and the US.华润三九在投资者互动中披露，积极布局细胞与基因治疗（CGT）领域，已有多个在研管线，并达成HiCM-188项目联合研发合作，该药为全球首个在中美两国同时获批临床的基于诱导多能干细胞的心衰再生治疗创新药。
Exhibitions & industry events展会与行业活动
2 · 2025-07-23 → 2026-05-22
▾
Participation in supply chain expos and pharmaceutical industry exhibitions showcasing company capabilities.参加供应链博览会和医药行业展会，展示公司能力。
2025-07-23Exhibited at the China International Supply Chain Expo (链博会) under theme 'Building a Modern TCM Quality Supply Chain', showcasing full-chain layout from seeds to end-products, integrating Kunming Pharma (昆药集团) and Tasly (天士力) advantages.参加中国国际供应链促进博览会，以“打造现代中药优质供应链”为主题，展示从种子到终端的全产业链布局，整合昆药集团和天士力优势。
2026-05-22China Resources Sanjiu, together with Kunming Pharma Group and Tasly Pharmaceutical Group, exhibited at the 92nd PHARMCHINA, showcasing the 'one body, two wings' business layout covering smart manufacturing, chronic disease management, and silver health.华润三九携昆药集团、天士力医药集团参展第92届全国药品交易会，展示‘一体两翼’业务布局，涵盖智能制造、慢病管理和银发健康。
GLP-1/GIP (BGM0504) partnershipGLP-1/GIP（BGM0504）合作
2 · 2025-08-01 → 2026-05-06
▾
Co-development agreement with Bright Gene Medicine for the GLP-1/GIP dual agonist BGM0504 for diabetes and obesity, with positive Phase III data.与博瑞医药就GLP-1/GIP双靶点激动剂BGM0504达成共同开发协议，用于糖尿病和肥胖症，III期数据积极。
2025-08-01China Resources Sanjiu signed a co-development agreement with Bright Gene Medicine for BGM0504 injection, a GLP-1/GIP dual agonist for T2DM and obesity, in mainland China. Bright Gene will receive up to CNY 282 million in R&D milestone payments and additional sales milestone payments.华润三九与博瑞医药就BGM0504注射液（GLP-1/GIP双靶点激动剂，用于2型糖尿病和肥胖症）在中国大陆签署合作研发协议。博瑞医药将获得最高2.82亿元研发里程碑付款及额外销售里程碑付款。
2026-05-06China Resources Sanjiu and Bright Gene Medicine announced Phase III clinical data for GLP-1/GIP dual-target drug BGM0504 for weight loss: average 19.3% weight reduction, 16.5 cm waist decrease, and significant blood pressure improvement.华润三九与博瑞医药公布GLP-1/GIP双靶点创新药BGM0504减重适应症III期临床数据：平均体重下降19.3%，腰围减少16.5cm，并显著改善血压。
Jiamusi TCM Industrial Park佳木斯中药产业园
1 · 2025-08-16
▾
Construction of a new TCM industrial park in Heilongjiang, including a major Banlangen granule production line.在黑龙江建设新的中药产业园，包括板蓝根颗粒生产线。
2025-08-16China Resources Sanjiu (Jiamusi) TCM Industrial Park project in Heilongjiang is under construction, with total investment of CNY 300 million (CNY 150 million for Banlangen project alone). Annual capacity: 500 million bags of Banlangen granules.华润三九（佳木斯）中医药产业园项目在建，总投资3亿元（其中板蓝根项目单独投入1.5亿元），建成后形成年产5亿袋板蓝根颗粒剂的生产规模。
Youyang capacity expansion (Maqin Zhike Syrup)酉阳扩产（麻芩止咳糖浆）
1 · 2025-10-10
▾
Technical renovation and capacity expansion project for the core product Maqin Zhike Syrup at the Youyang subsidiary.酉阳子公司核心产品麻芩止咳糖浆的技术改造和产能扩建项目。
2025-10-10China Resources Sanjiu (Youyang) Pharmaceutical Co., Ltd. launched a technical renovation and capacity expansion project for its core product Maqin Zhike Syrup, aiming to significantly boost production capacity and build modern warehousing and logistics facilities.华润三九（酉阳）制药有限公司启动核心产品麻芩止咳糖浆的技改扩能项目，旨在大幅提升产能，并配套建设现代化标准库房与仓储物流设施。
Clarifications & corrections澄清与更正
1 · 2026-01-20
▾
Public clarifications on subsidiary status and data integrity issues.关于子公司状态和数据完整性问题的公开澄清。
2026-01-20Clarified that 'Chukangjia Health' is not a subsidiary or invested project; only OEM cooperation via Huaren Shenghai division.澄清“初康家健康”非子公司或投资项目，仅通过华润圣海事业部进行委托代工合作。
R&D progress & pipeline研发进展与管线
1 · 2026-08-21
▾
Updates on R&D investment, clinical trials, and regulatory approvals for new drugs.研发投入、临床试验和新药监管审批的最新进展。
2026-08-21H1 report: R&D investment RMB 731m (+10.51% yoy); Class 1.1 TCM innovative drug Zaoren Ningxin Dripping Pills (for insomnia with heart-liver blood deficiency) approved in June; BGM0504 injection weight-loss indication NDA accepted by CDE, T2DM phase III ongoing; HiCM-188 in confirmatory trial.半年报：研发投入7.31亿元（同比+10.51%）；中药1.1类创新药枣仁宁心滴丸6月获批上市（用于失眠症心肝血虚证）；BGM0504注射液减重适应症NDA获CDE受理，2型糖尿病III期临床推进中；HiCM-188进入确证性临床试验。
